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2. Introduction 
To say that obesity is caused by merely consuming too many calories is like saying that the 
only cause of the American Revolution was the Boston Tea Party. 
 Adelle Davis (1904 - 1974), American author and a pioneer in the field of nutrition 
 
With this statement Adelle Davis highlighted obesity's complex chain of causation. Equally 
complex are the consequences of obesity, of which one, type 2 diabetes, is the focus of this 
thesis. Firstly, the effectiveness of fasting glucose in the screening for type 2 diabetes is 
addressed; secondly, the associations between several anthropometric characteristics and type 
2 diabetes are explored; and finally, the effects of gastric bypass surgery and intensive 
lifestyle intervention on obesity-related cardiovascular risk factors and beta cell function are 
compared. The participants of the studies included in this thesis were either morbidly [body 
mass index (BMI) ≥ 40 or ≥ 35 kg/m2 with a weight-related comorbidity] or extremely (BMI 
≥ 40 kg/m2) obese, and were all recruited from the Morbid Obesity Centre at Vestfold 
Hospital Trust in Tønsberg. The first study used receiver operating characteristics (ROC) 
curve analyses to examine the diagnostic accuracy of fasting glucose to predict type 2 
diabetes in 1 253 morbidly obese patients. Although obesity is known to influence the 
sensitivity and specificity of fasting glucose for the detection of type 2 diabetes, this had not 
been previously examined in morbidly obese subjects. The second study in this thesis had a 
cross-sectional design and addressed the association between measures of central and general 
obesity and type 2 diabetes in extremely obese patients (n = 1 003). The third and fourth 
studies used data from the one-year non-randomised clinical MOBIL (Morbid Obesity 
treatment, Bariatric surgery versus Intensive Lifestyle intervention) study. In this study 80 
patients were treated with Roux-en-Y gastric bypass surgery and 66 patients received 
intensive lifestyle intervention at a rehabilitation centre.  The third study addressed changes in 
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type 2 diabetes and other obesity-related cardiovascular risk factors, whereas the fourth study 
explored changes in beta cell function estimated by indices including glucose, insulin and 
proinsulin obtained during an oral glucose tolerance test (OGTT). Although changes in 
metabolic parameters after both bariatric surgery and lifestyle interventions programmes have 
been reported previously, few have compared such treatments in head-to-head studies.  
 
2.1. Obesity 
Throughout most of human history, securing an adequate energy intake to meet daily 
requirements has been a major nutritional problem. However, today, along with rising 
standards of living, obesity, the result of over-nutrition, has become a major threat to the 
health of populations in countries all over the world (1). In fact, “globesity” has become more 
of a problem than under-nutrition and infectious diseases and, paradoxically, co-exists with 
problems related to under-nutrition in many developing countries (1).  
 
2.1.1. Definition of obesity 
Obesity is a medical condition in which excess body fat has accumulated to the extent that it 
may impair health (1). The degree of obesity is most commonly classified according to the 
BMI [defined as the weight divided by the square of the height (kg/m2)] (Table 1). In 
addition, other anthropometric measures, and especially measures of abdominal obesity, have 
been used to identify subjects at risk of obesity related metabolic conditions. Due to different 
patterns of fat accumulation in men and women sex-specific cut-off values exist. In 
Caucasians, waist-to-hip ratio (WHR) > 1.0 in men and > 0.85 in women indicates abdominal 
fat accumulation (2). Furthermore, cut-off point for waist circumference (WC), which may 
provide a more practical correlate of abdominal fat distribution than WHR, has been 
suggested (Table 2).  
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Table 1. The World Health Organisation`s (WHO) classification of obesity (1). 
 BMI (kg/m2) Risk of comorbidities 
Underweight < 18.5 Low 
Normal 18.5 – 24.9 Average 
Overweight ≥ 25.0  
   Preobese 25.0 – 29.9 Increased 
   Obese class I 30.0 – 34.9 Moderate 
   Obese class II 35.0 – 39.9 Severe 
   Obese class III* ≥ 40.0 Very severe 
*Extreme obesity 
 
Table 2. Sex-specific waist circumference and risk of metabolic complications associated 
with obesity in Caucasians (3). 
 Waist circumference (cm) 
Risk of metabolic complications Men Women 
Increased   ≥ 94 ≥ 80 
Substantially increased ≥ 102 ≥ 88 
 
2.1.2. Obesity trends  
Estimates indicate that more than 300 million people are obese worldwide (4). Data from the 
National Health and Nutrition Examination Survey (NHANES) show that the prevalence of 
obesity in US adults has more than doubled from 15 % in the late seventies up to 31 % in the 
year 2000 (5). Results from large telephone surveys in the US show that from 1986 to 2005 
the increase in self-reported obesity has been greatest amongst those with the severest degree 
of obesity (6). During this period the prevalence of BMI ≥ 30, 40 and 50 kg/m2 increased by 
12 
approximately 200, 500 and 1000 %, respectively (6). Interestingly, data from 2008 indicate 
that the obesity epidemic seems to be flattening out in the US, especially among women (7). 
Still, 32 % of US adults are obese, with 4 % of men and 7 % of women being extremely obese 
(7). Correspondingly, the prevalence of obesity among women and men aged 40-44 years has 
increased in Norway the last three to four decades (Figure 1) (8). Three major health surveys 
in the county of Nord-Trøndelag in Norway, The Nord-Trøndelag Health Study (HUNT 1, 2 
and 3), have shown that the prevalence of obesity has increased from 7.8 to 14.4 to 22.1 % in 
men and from 13.6 to 18.6 to 23.2 % in women from 1984-86 to 1995-97 to 2006-08, 
respectively (9). The greatest increase was seen in those less than 40 years of age (9). Results 
from other health surveys performed in five Norwegian counties in 2000-03 showed that the 
prevalence of BMI ≥ 35 and ≥ 40 kg/m2 were approximately 3 and 0.5 % in men and 5 and 1 
% in women, respectively (10). Based on these figures, we can assume that the overall 
prevalence of morbid obesity in Norway is around 2 %. 
 
Figure 1. Proportion of Norwegian women and men aged 40-44 years with BMI ≥ 30 kg/m2 from 1965 to 2002. 
Modified figure from The Norwegian Institute of Public Health with permission from A. Engeland (8). 
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2.1.3. The burden of obesity 
Recently, the WHO estimated that obesity and two of its most common metabolic 
consequences, hyperglycaemia (11-21) and high blood pressure (19-22), alongside tobacco 
usage and physical inactivity, represent the five leading global risks to mortality (23). The 
positive association between BMI and all-cause and cardiovascular mortality is documented 
in numerous studies (24-32). One large study, including almost  900 000 subjects with a mean 
age of 46 years, showed that during a mean follow-up period of 8 years the median survival 
was reduced by 8 to 10 years for subjects with a BMI of 40 to 45 kg/m2 compared to subjects 
with a BMI of 22.5 to 25 kg/m2 (29). Importantly, higher mortality rates among obese subjects 
seem to be mainly explained by obesity related co-morbidities such as hypertension and type 
2 diabetes rather than by obesity alone (33).  
 
Several other cardiovascular risk factors, such as metabolic syndrome, albuminuria, left 
ventricular hypertrophy and low grade inflammation, are all closely associated with obesity 
(34-37). Furthermore, obesity is a risk factor for cancer (38), urinary incontinence (39), 
gastro-oesophageal reflux (40), obstructive sleep apnoea (41), osteoarthritis (42), depression 
(43) and reduced quality of life (44). 
 
Several lines of evidence indicate that it is not only the total amount of fat but the distribution 
of fat that determines the risk associated with obesity. Excess intra-abdominal fat, which can 
be assessed using imaging techniques, seems to be an independent predictor of metabolic risk 
factors (45-48). Due to the strong correlation between anthropometric measures of abdominal 
obesity and visceral adipose tissue deposition (46,49), these measures have  been widely used 
as surrogate measures of intra-abdominal fat mass in order to identify subjects at risk. Indeed, 
several large cross-sectional and longitudinal population studies indicate that WC and/or 
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WHR are more strongly associated with type 2 diabetes and other obesity related disorders 
than BMI (11-19). Furthermore, one large case-control study including 27 000 participants 
showed that WHR and WC, but not BMI, were independently associated with the risk of 
myocardial infarction (50). Finally, some studies indicate that WHR is a better predictor of 
death than BMI (19,51,52). 
 
2.2. Type 2 diabetes 
Hand in hand with the rising obesity rate is the substantial increase of diabetes worldwide (53-
55). Due to the strong association between diabetes and obesity the coexistence of these 
conditions has been referred to as “diabesity” (56). The term reflects both the etiological and 
clinical presentation of this phenomenon. Women and men with BMI ≥ 35 kg/m2 have 93 and 
42 times higher risk of type 2 diabetes than those with the lowest risk (57,58). 
 
2.2.1. Definition of type 2 diabetes 
The diagnosis of type 2 diabetes and its intermediate forms has been debated for decades, and 
the diagnostic criteria have been changed several times: In the late nineties the fasting glucose 
cut-off level was lowered from 7.8 to 7.0 mmol/l (59,60); in 2003 the American Diabetes 
Association (ADA) lowered the threshold for impaired fasting glucose (IFG) from 6.1 to 5.6 
mmol/l (61); and finally in 2010 ADA included the use of HbA1c to diagnose diabetes 
(HbA1c  ≥ 6.5 %) and to identify subjects at “increased risk for future diabetes” (HbA1c 5.7 – 
6.4 %) (62). The current diagnostic criteria for diabetes and intermediate hyperglycaemia 
according to the WHO and ADA are shown in Table 3. 
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Table 3. Diagnostic criteria for diabetes and intermediate hyperglycaemia according to 
serum/plasma glucose levels. 
 WHO 2006 (63) ADA 2010 (62) 
Diabetes mellitus   
Fasting glucose ≥ 7.0 mmol/l ≥ 7.0 mmol/l 
 Or or 
2-hour glucose ≥ 11.1 mmol/l ≥ 11.1 mmol/l1 
  or 
HbA1c  ≥ 6.5 % 
Increased risk for future diabetes  
Fasting glucose2 6.1 – 6.9  mmol/l 5.6 – 6.9 mmol/l 
 and/or and/or 
2-hour glucose3 7.8 – 11.0 mmol/l 7.8 – 11.0 mmol/l1 
  and/or 
HbA1c  5.7 – 6.4 % 
1Corresponding values for capillary plasma are ≥ 12.2 mmol/l for diabetes mellitus and 8.9 – 
12.2 mmol/l for pre-diabetes. 2Impaired fasting glucose. 3Impaired glucose tolerance. 
 
2.2.2. Type 2 diabetes and cardiovascular risk 
The scientific evidence for the current thresholds is mainly based upon an increased risk of 
retinopathy above these cut-off levels (Figure 2) (59,64). However, these cut-off points are 
still arbitrarily chosen, and some publications indicate that there exists no consistent 
glycaemic threshold when the risk of retinopathy increases (65,66). The latter findings are 
consistent with observations indicating that no glucose cut-off value exists in which the risk 
of macrovascular complications and death increases (67-69). This is analogous to end-organ 
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damage found with other cardiovascular risk factors such as blood pressure and serum 
cholesterol levels, where the associations are continuous (70,71). Despite the limitations with 
the data from which the diagnostic criteria for diabetes are derived, the current criteria 
distinguish a group with significantly increased premature mortality and increased risk of 
microvascular and macrovascular complications (64-68,72-77).   
 
 
 
Figure 2. Five year 
cumulative incidence (top) 
and prevalence (bottom) of 
retinopathy by deciles of 
the distribution of fasting 
plasma glucose, two hour 
plasma glucose and 
glycated haemoglobin A1 
and A1c in Pima Indians. 
Reproduced from McCane 
et al. (64) with permission. 
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2.2.3. Diabetes trends 
During a 15 year period from 1985 to 2000, the estimated number of people with diabetes 
worldwide increased from 30 to 171 million, and the prevalence is likely to increase to at least 
366 million by 2030 (55). Norway is no exception: Data from the HUNT surveys indicate an 
increase in the prevalence of diabetes during the last two decades (9,78), with 3.8 % of 
women and 4.9 % of men having diagnosed diabetes in 2006-08 (9).  Including subjects with 
unknown diabetes would probably double these figures (79). There is an increase in the 
prevalence of diabetes within each obesity category, and among the extremely obese 
approximately one out of four has diabetes (21).  
 
2.2.4. Screening for type 2 diabetes 
Screening, the, search for undiagnosed conditions/diseases in asymptomatic subjects, is only 
appropriate under given circumstances. Some important criteria and their relevance to 
screening for type 2 diabetes are shown in Table 4 (80).  
 
Table 4. Screening for type 2 diabetes (80) 
Criteria Met for diabetes 
Important health problem Yes 
Natural history of the disease is known Yes 
Asymptomatic period Yes 
Early treatment improves outcome Probably 
Available and reliable test Yes 
Reasonable costs/Available treatment Unclear/Yes 
Systematic and ongoing process Unclear 
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Type 2 diabetes is undoubtedly an important health problem, the natural history of the disease 
is known, the disease has an asymptomatic period and reliable tests and treatments exist; all 
of which is supportive of screening for type 2 diabetes. However, the beneficial effects of 
early intervention (see below, 2.3.3) are unclear. Moreover, it is uncertain whether the costs 
of screening and treating type 2 diabetes are reasonable in relation to total health 
expenditures. In addition, it is also unclear how a screening programme should be organised 
and how often the tests should be repeated.  
 
The screening test should ideally have high sensitivity (proportion of people with the disease 
who have a positive test) and high specificity (proportion of people without the disease who 
have a negative test). In addition, the test should be valid (reflect the true status of the 
individual), reliable (reflect the degree to which the results obtained by any given procedure 
can be replicated) and reproducible (reflect the test`s ability to obtain similar or identical 
results on repeated measurements on the same subject). The predictive value of a test 
(probability that a person has or does not have the disorder given the result of the test) 
depends both on the tests sensitivity and specificity but also on the prevalence of the disorder 
in the population being screened. Thus, in the case of diabetes screening, the positive 
predictive value of a positive test is higher in a population with a high prevalence of diabetes 
than in a population with a low prevalence. This explains why selective screening 
programmes for type 2 diabetes, for example in out-patient clinics and opportunistic 
screening (case finding) in high risk patients, may be more appropriate than population based 
screening programmes.  
 
In general, despite  lack of evidence, it is recommended that subjects with BMI ≥ 25 kg/m2 
and age ≥ 45 years should be tested every third year (81). Furthermore, it is recommended 
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that persons with additional risk factors, including severe obesity, should be tested 
independent of their age. In line with these recommendations, all patients attending the 
Morbid Obesity Centre for the first time are screened for type 2 diabetes.  
 
2.2.5. The pathogenesis of type 2 diabetes 
Insulin is a hormone produced by the pancreatic β-cells and is the key hormone for the 
regulation of blood glucose. The hormone stimulates uptake of glucose from the blood in the 
muscle and fat tissue, storage of glucose as glycogen in the liver and muscle cells 
(glycogenesis) and uptake and esterification (conversion into triglycerides) of fatty acids in 
adipocytes. Furthermore, insulin inhibits the breakdown of proteins (proteinolysis), the 
hydrolysis of triglycerides (lipolysis) and the production of glucose from amino acids, lactate 
and glycerol (gluconeogenesis). Glucagon, which is also secreted by the pancreas, has the 
opposite effects to that of insulin. The hormone causes the liver to convert stored glycogen 
into glucose and thereby increases blood glucose. In addition, glucagon stimulates insulin 
secretion so that glucose can be taken up by insulin dependent tissues. Thus, glucagon and 
insulin are part of a feedback system that keeps blood glucose at the right level. 
 
Hyperglycaemia occurs when the balanced interplay between insulin`s action and release is 
disrupted. However, the causes for hyperglycaemia are complex and multi-factorial and 
include genetic and environmental factors that affect insulin secretion and insulin sensitivity. 
Firstly, older age is a major risk factor for diabetes (21,79). The prevalence of diabetes is 
approximately three times higher in subjects aged between 70-79 years than it is in those aged 
50-59 years (79). Secondly, lack of exercise has been shown to be a independent risk factor 
for type 2 diabetes (82). Thirdly, a positive family history confers a 2.4 fold increased risk for 
type 2 diabetes (83).  Fourthly, as mentioned, obesity is major risk factors for type 2 diabetes 
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(11-19). In recent years it has become clear that the adipose tissue is not only a passive 
storage depot for fat but rather an active endocrine organ expressing and secreting a variety of 
bioactive proteins with metabolic effects on distant cells and tissues (84,85). Non-esterified 
fatty acids, adipokines and inflammatory mediators released by adipocytes, especially from 
adipocytes located in the visceral adipose tissue, cause insulin resistance in the liver and 
skeletal muscle by adversely affecting the insulin signalling cascade (84-86). Consequently, 
gluconeogenesis and lipogenesis in the liver are stimulated and glucose uptake in the skeletal 
muscle inhibited, eventually resulting in hyperglycaemia and triglyceridaemia. In turn, these 
conditions will feedback and worsen both insulin sensitivity and β-cell function (gluco- and 
lipo-toxicity) (84,85,87,88).  
 
The relationship between insulin sensitivity and insulin secretion displays a hyperbolic curve 
(Figure 3) (89,90). This denotes that the product of insulin secretion and insulin sensitivity, 
known as the disposition index (DI), is constant. Due to this feedback mechanism, normal 
blood glucose levels can be maintained in the presence of insulin resistance, as with obesity, if 
the insulin secretion is regulated adequately. As shown in Figure 3 (91), normoglycaemia is 
preserved when a reduction in insulin sensitivity is accompanied by an increase in insulin 
secretion. By contrast, impaired glucose tolerance (IGT) and type 2 diabetes occur when the 
insulin release is insufficient for a given degree of insulin sensitivity.    
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Figure 3. Changes in insulin secretion [acute insulin response (AIR) to intravenous glucose] relative to changes 
in insulin sensitivity [hyperinsulinaemic euglycaemic clamp (M-low)] in 11 Pima Indian subjects in whom 
glucose tolerance deteriorated from normal (NGT) to impaired (IGT) to diabetic (DIA) (Progressors), and in 23 
subjects who retained NGT (Non-progressors). The lines represent the prediction line and the lower and upper 
limits of the 95% confidence interval of the regression between AIR and M-low as derived from a reference 
population of 277 Pima Indians with NGT. Reproduced from Weyer et al. (91) with permission. 
 
2.3. Obesity treatment 
The two main principles in the treatment of obesity are to reduce energy intake and to 
increase energy expenditure through lifelong behavioural changes. Medical management 
includes lifestyle intervention strategies compromising of dietary modifications, physical 
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activity, psychological interventions and anti-obesity drugs. Additionally, weight loss 
(bariatric) surgery can be used in those with the severest degree of obesity. 
 
2.3.1. Medical management of obesity 
The macronutrient composition of various weight loss diets is a topic of great interest, and 
several randomised controlled trials have addressed this question (92-102). Most studies 
indicate that low-carbohydrate diets yield greater short-term weight loss than low-fat diets 
(92-98). In a two-year trial that included 322 moderately obese subjects, mean weight loss 
was significantly greater after low-carbohydrate and Mediterranean diets than after a low-fat 
diet (5.5, 4.6 and 3.3 kg, respectively) (92). In line with these observations, a recent Cochrane 
review confirmed that low-carbohydrate diets were associated with a one kg greater weight 
loss than other diets (103). Moreover, two other recent Cochrane reports addressing obesity 
treatment have been published (104,105). In the first, exercise alone is shown to result in up to 
four kg weight loss, and when combined with a diet to result in approximately one kg greater 
weight reduction than diet alone (104). The second report shows that behavioural and 
cognitive-behavioural strategies alone result in three kg weight loss and that when combined 
with lifestyle interventions weight reduction is enhanced (105).  
 
The use of orlistat, sibutramine and rimonabant in addition to lifestyle modifications have, in 
randomised placebo-controlled trials with a follow-up period of one year or longer, been 
shown to increase weight reductions in overweight and obese subjects (106-111). A recent 
meta-analysis showed that compared to placebo, orlistat, sibutramine and rimonabant reduced 
weight by 3, 4 and 5 kg, respectively (112). Anti-obesity drugs are also effective in preventing 
weight regain after an initial weight reduction (106-108,113), improving several metabolic 
conditions (106-116) and preventing the development of type 2 diabetes (117). Despite these 
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promising results the development of pharmacological therapies for the treatment of obesity 
has, due to serious side-effects, been a great disappointment. In 1997, fenfluramine, another 
weight-loss drug, was withdrawn from the U.S. market after reports of pulmonary 
hypertension and valvular heart disease (117). Later in 2008, rimonabant was withdrawn from 
the European market due to psychological side-effects (118), and the CRESCENDO study, 
which aimed to assess whether rimonabant could prevent cardiovascular event, was 
prematurely terminated (119). Finally, in 2010 the European Medicines Agency advisory 
committee recommended that sibutramine be withdrawn from the European market (120) due 
to increased risk for cardiovascular events reported among sibutramine-users in the SCOUT 
study (121).  
 
The Finnish Diabetes Prevention Study, the Diabetes Prevention Program and the LookAhead 
trial, which all included overweight and obese subjects with IFG, IGT or type 2 diabetes, have 
all shown that dietary modifications and physical activity may result in 5 to 8 % weight loss 
after one year and 4 to 6 % weight loss after three to four years (122-126). Studies including 
solely morbidly obese subjects have shown that intensive lifestyle interventions, including 
low calorie-diets, physical activity and frequent meetings or institutionalisations, can result in 
8 to 20 % weight reduction after 5 to 24 months (127-131).  However, with no intervention in 
the follow-up period two thirds of the initial weight loss was regained two to four years after 
institutionalisation (128). Having a high physical activity level, sticking to a structured low-
calorie diet and self-monitoring weight are important predictors of long-term weight loss 
maintenance (132). Additionally, regular personal contact in the weight maintenance follow-
up period seems to help sustain weight loss (133).  
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2.3.2. Bariatric surgery 
Due to the limited long term success of medical management of obesity, various surgical 
techniques have been developed during the last few decades (134-136). Along with the rising 
prevalence of severe obesity and the introduction of safer procedures and techniques, the 
number of bariatric operations performed worldwide has increased dramatically during the 
last decade; from 40 000 in 1998  to 340 000 in 2008 (137). Norway is no exception, with 
around 1 500 bariatric surgery operations performed in 2008 (137). To date, the annual 
number of operations is around 2000. 
 
Surgical techniques 
The procedures can be divided into three according to the mechanism by which they induce 
weight loss: Restrictive procedures reduce food intake by restricting gastric volume; 
malabsorptive procedures reduces energy uptake from the intestinal track by bypassing parts 
of the small intestine; whilst combined procedures do both. Such procedures began in the mid 
1950s with the jejunoileal bypass, which is a purely malabsorptive procedure. Despite good 
weight loss this procedure was abandoned as many developed severe malnutrition, liver 
failure and diarrhea (138). In the 1980s and 1990s vertical banded gastroplasty and gastric 
banding with fixed band were commonly performed. However, these purely restrictive 
procedures often caused stenosis, persistent vomiting, acid reflux and ulcers, leading them to 
be replaced by other procedures.  
 
The gastric bypass procedure is a combined restrictive and malabsorptive procedure and was 
initially developed by Mason and Ito in the 1960s (139). Over several decades the gastric 
bypass has been modified into its current form, and accounts today for almost 50 % of all 
bariatric operations performed worldwide (137) and for around 90 % of all procedures 
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performed in Norway (140). A Roux-en-Y gastric bypass first divides the stomach into a 
small upper pouch of about 30 ml and a much larger, lower "remnant" pouch. The small 
gastric pouch is then anastomosed to a Roux-en-Y proximal jejunal segment (Figure 4).  
 
 
Figure 4. Illustration of the Roux-en-Y gastric bypass procedure. Illustration by Ole-Jacob Berge. Reproduced 
from Aasheim et al. (140) with permission. 
 
The Roux-en-Y gastric bypass operations are often referred to as standard, long limb, or 
distal, depending on the length of the Roux (alimentary) limb. The long limb procedure which 
includes an alimentary limb of about 150 cm, a biliopancreatic limb of about 80 cm and a 
common channel of 2 to 5 meters (depending on the length of the small intestine), is most 
commonly used in Scandinavia (141,142).  
 
Alimentary limb 
Biliopancreatic limb 
Common channel 
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Other bariatric procedures performed worldwide today include adjustable gastric banding (42 
%), sleeve gastrectomy (5 %), and biliopancreatic diversion with or without duodenal switch 
(2 %) (137). Adjustable gastric banding uses an inflatable silicone device that is placed 
around the top portion of the stomach in order to reduce food intake. Although popular 
abroad, this operation is hardly performed in Norway. Sleeve gastrectomy reduces the 
stomach to a banana shaped tube by removing a large portion of the stomach. The operation 
can be used as a single procedure or as the first step in a two step procedure where the second 
is a conversion into duodenal switch. The biliopancreatic diversion includes either a 
horizontal gastrectomy with a gastro-jejunal anastomosis or a vertical gastrectomi with a 
duodenon-jejunal anastomosis. Both procedures include a short common limb (50-100 cm) 
and are highly malabsorptive.  
 
The introduction of laparoscopic approaches during the last decade has reduced the time spent 
in hospital (143,144), post-operative pain (144), the number of incisional hernias (143,145) 
and mortality (146-148). For these reasons more than 90 % of bariatric procedures performed 
worldwide today are now performed laparoscopically (137).  
 
Outcomes 
Substantial and long term weight reduction and improvements in metabolic conditions after 
bariatric surgery are reported in a number of large case series (149-153), a few studies 
comparing bariatric surgery with lifestyle interventions (154-158) and in two meta-analyses 
(159,160). Especially worth noting is the large case-controlled Swedish Obese Subjects (SOS) 
study which prospectively included more than 2000 patients undergoing bariatric surgery and 
as many conservatively treated patients (154), and, in addition, the two randomised controlled 
trials by Dixon and O`Brian which compared the effect of adjustable gastric banding and 
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lifestyle intervention on weight and type 2 diabetes in adults (155,156). Weight loss is 
greatest after malabsorptive procedures and least after purely restrictive operations: One year 
weight reduction after banding, gastric bypass and biliopancreatic diversion is approximately 
20, 30 and 40 %, respectively (154,156,159). Bariatric surgery seems especially effective in 
improving glycaemic control, with a remission rate of type 2 diabetes higher than 70 % two 
years after surgery reported in both the SOS study and the randomised controlled trial by 
Dixon and O`Brian (154,156). However, it should be noted that the criteria for remission type 
2 diabetes in these studies varied, thereby making comparison difficult. In addition, the SOS 
study documented that bariatric surgery reduced blood pressure, triglycerides and total 
cholesterol and increased high density lipoprotein cholesterol (154). Moreover, surgical 
treatment of obesity has shown to ameliorate metabolic syndrome (152,155,156), albuminuria 
(161,162), left ventricular hypertrophy (163,164), low-grade inflammation (165,166) and 
obstructive sleep-apnoea (167,168). In addition, bariatric surgery improves psychosocial 
functioning and health related quality of life (169,170). Finally, both the SOS study and a 
retrospective cohort study by Adams et al. indicate that bariatric surgery is associated with 
reduced mortality (171,172). 
 
Although the mortality rate after bariatric surgery has shown a downward trend since 1990 
(173), no procedure is without risk. The longitudinal assessment of bariatric surgery 
consortium reported total mortality of 0.3 % within 30 days in 4 610 patients who had a first-
time bariatric procedure (147). The mortality rate was 0 % after laparoscopic adjustable 
gastric banding and 0.2 and 2.1 % after laparoscopic and open Roux-en-Y gastric bypass, 
respectively (147). Correspondingly, total 30 days mortality rate was 0.28 % in a meta-
analysis by Buchwald (173). Partly contrasting these findings, 2 % of the Medicare 
beneficiaries undergoing bariatric surgery died within 30 days (174). However, it should be 
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noted that the study population in the latter study had a higher men age and a higher 
proportion of men than other studies reporting mortality after bariatric procedures. Both high 
age and male gender are associated with increased risk of post-operative death and may 
explain some of these differences (146,173,174). Thromboembolic diseases, bleedings, small 
bowel obstruction and leakage are the most common causes of postoperative death and 
account for the majority of non-fatal complications (146-148,175). Long term complications 
after Roux-en-Y gastric bypass include gastrointestinal symptoms such as nausea, vomiting, 
postprandial regurgitation, dumping syndrome and diarrhea (176), micronutrient deficiencies 
(177-179), marginal ulcers (180,181), postprandial hypoglycaemia (182,183) and small bowel 
obstructions (184).  
 
2.4. Treatment of type 2 diabetes 
The main goal of type 2 diabetes treatment is to maintain a good quality of life and to 
minimize the risk of future microvascular and macrovascular complications. Lifestyle 
interventions have shown to improve glyceamic control in overweight and obese diabetic 
subjects (125,126). However, in the long-term, most diabetic subjects need glucose lowering 
drugs in order to prevent hyperglycaemia. Both the randomised controlled UK Prospective 
Diabetes Study (UKPDS) and the Kumamoto study have demonstrated that intensive blood 
glucose control with insulin, sulphonylureas and metformin reduce the risk of microvascular 
complications (185-187). In addition, the ten year post-trial follow-up of the UKPDS 
indicates that intensive glucose lowering treatment can reduce the risk of myocardial 
infarction and death of any cause (188). However, three recent major cardiovascular outcome 
trials [the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study (189), the 
Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation 
(ADVANCE) trial (190) and Veterans Affairs Diabetes Trial (VADT) (191)] of intensive 
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diabetes therapies in patients with type 2 diabetes found no significant reduction in 
cardiovascular events. The ACCORD study actually reported a 22 % increase in total 
mortality in the intensive treated group. However, when the studies are combined, there is 
agreement both that non-fatal coronary episodes are reduced by intensive control and that the 
incidences of stroke, cardiovascular mortality and total mortality remain unaltered (192-194). 
Both national and international guidelines recommend that the goal of glucose lowering 
therapy should be HbA1c ≤ 7 % (81,195). Moreover, high blood pressure and dyslipidaemia 
should be treated aggressively in diabetic subjects in order to prevent cardiovascular 
complications (81). Norwegian data indicate that only a small number of type 2 diabetic 
subjects reach the combined targets for glucose, blood pressure and cholesterol control (196). 
 
In recent years, new classes of glucose-lowering agents such as thiazolidinediones, glucagon-
like peptide-1 agonists and dipeptidyl peptidase 4 inhibitors have become available and   
increased the number of treatment options for type 2 diabetes. In 2008 ADA and the European 
association for the study of diabetes jointly reviewed the current literature and based on the 
effectiveness, safety and cost of the different therapies published an algorithm for the medical 
management of hyperglycaemia in type 2 diabetes (197). The study group recommended that 
lifestyle modifications and metformin should be the initial therapy, with further treatment 
including either insulin or sulphonyureas. Alternatively, less validated treatments could be 
used. The statement also included, for the first time, bariatric surgery as an alternative for the 
treatment of type 2 diabetes in subjects with BMI ≥ 35 kg/m2 (197).  
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3. Aims of the thesis 
The aims of the studies in this thesis are: 
 
Paper I 
 To assess the effectiveness of fasting glucose in  detecting undiagnosed diabetes in 
morbidly obese subjects 
 
Paper II 
 To explore in extremely obese subjects the relationship between various measurements 
of obesity and type 2 diabetes   
 
Paper III 
 To compare changes in obesity-related cardiovascular risk factors after gastric bypass 
surgery and intensive lifestyle intervention 
 
Paper IV 
 To compare changes in beta cell function after gastric bypass surgery and intensive 
lifestyle intervention 
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4. Research design and methods 
4.1. Participants and study design 
This thesis is based on both studies using cross-sectional data from The Morbid Obesity 
Biobank Registry and from the one year non-randomised controlled clinical MOBIL study 
(Table 5). All participants were referred from secondary health care clinics to the Morbid 
Obesity Centre at Vestfold Hospital Trust located in Tønsberg. The centre was established in 
September 2004 and had at first a temporary organisational form (Overvektsprosjektet i Helse 
Sør). Later, in 2007, it was established as a permanent centre and is today one  of two tertiary 
health care centres in the South-Eastern Norway Regional Health Authority treating morbidly 
obese patients. The main tasks of the centre are to 1) evaluate, assess and treat morbidly obese 
subjects, 2) conduct research in the field of obesity and 3) educate and support other health 
care centres treating obese patients.  
 
Table 5. Study design, population and sample size of the studies.  
Paper Study design Population Participants 
I Cross-sectional Morbidly obese 1 253 
II Cross-sectional Extremely obese 1 003  
III One year non-randomised  Morbidly obese 80 gastric bypass 
66 lifestyle 
IV One year non-randomised  Morbidly obese 64 gastric bypass 
55 lifestyle 
29 normal weight controls 
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4.1.1. The Morbid Obesity Biobank Registry 
Paper I and II had cross-sectional designs and included patients registered in The Morbid 
Obesity Biobank Registry. Since December 2005, all patients who attend the Morbid Obesity 
Centre and give informed consent are consecutively included in the Registry. Clinical data 
from the patients’ first visit, along with the results of the laboratory analyses performed the 
same day, are recorded on standardised forms and included in the Registry. In addition, results 
of OGTTs performed one year before or after the first visit were, until November 2008, 
included.   
 
Paper I included all the morbidly obese patients registered in the Morbid Obesity Biobank 
Registry as of November 2008 (n = 1 329). After the exclusion of 76 subjects due to; type 1 
diabetes mellitus (n = 11), prior non-reversed bariatric surgery (n = 10), usage of oral 
corticosteroids (n = 21) or BMI < 35 kg/m2, a total of 1 253 subjects were included in the 
analyses. 
 
Paper II included extremely obese patients registered in the Registry by January 2009 (n = 1 
068). In this study 65 subjects were excluded due to; prior non-reversed bariatric surgery (n = 
6), missing glucose measurements (n = 5), type 1 diabetes (n = 6), usage of oral 
corticosteroids (n = 16) and non-Caucasian ethnicity (n = 32). Consequently, a total of 1 003 
subjects were included in the analyses. 
 
4.1.2. The MOBIL study 
Paper III and IV included patients from the MOBIL study. The flow of the study participants 
is shown in Figure 5. Firstly, during a six month period, between December 2005 and May 
2006, 228 consecutive patients attending the Morbid Obesity Centre for the first time were 
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pre-screened for participation in the study. Secondly, 181 patients who satisfied the criteria 
for bariatric surgery (198) and wanted either gastric bypass surgery or intensive lifestyle 
intervention were referred to a screening examination which included an oral glucose 
tolerance test, 24-hour ambulatory blood pressure monitoring, a somnography, pulmonary 
function tests, quality of life questionnaires and a structured dietary interview. The elapsed 
period of time between the pre-screening examination and the screening examination was 18 
(11) weeks. Finally, 146 subjects were accepted for either gastric bypass surgery (n = 80) or 
intensive lifestyle intervention (n = 66) and were enrolled in the study.  
Pre-screened (n=228)
Screened (n=181)
Not eligible (n=47)
Completed the 
study (n=76)
Not enrolled (n=35)
-BMI<35 kg/m2 (n=3)
-Previous malabsorptive surgery (n=3)
-Pregnancy (n=2)
-Withdrew (n=17)
-Postponed treatment (n=4) 
-Alternative bariatric procedures (n=6)
Withdrew (n=2)
Excluded due to 
pregnancy (n=2)
Completed the 
study (n=63)
Withdrew (n=2)
Excluded due to 
cancer (n=1)
Intensive lifestyle 
intervention (n=66)
Gastric bypass 
surgery (n=80)
Enrolled (n=146)
 
Figure 5. Flow of participants throughout the MOBIL study. Reproduced from Hofsø et al (199), no permission 
required. 
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The time between the screening examination and either the date of surgery or the start of 
lifestyle intervention was, due to a waiting list for surgery, significantly longer in the surgery 
group than in the lifestyle group, 65 (14) versus 19 (15) weeks (P < 0.001). One year follow-
up was completed by June 2009. The completion rate within both groups was 95 % (76 in the 
surgery group and 63 in the lifestyle group). 
 
Allocation to treatment was made as a joint decision between the patient and the physician. 
All patients underwent a thorough assessment conducted by a multidisciplinary team 
consisting of an internist, a dietician and, in cases of surgery, a surgeon prior to treatment. 
These health professionals provided complete information about the possible risks and 
benefits of an operation and encouraged patients to incorporate their own values and 
preferences into the decision-making process.  
 
Patients in the surgical group completed a low calorie diet (800 to 900 kcal/day) in the three 
to six weeks preceding surgery. A Roux-en-Y gastric bypass was performed laparoscopically 
in 74 of the 76 surgically treated patients. The gastric pouch was about 25 ml, whilst the 
intestinal limb lengths were measured as follows: alimentary limb, median 120 (range 80 to 
250) cm; biliopancreatic limb, median 100 (range 50 to 170) cm; and common channel, 
variable length. To optimise the result of the procedure patients were encouraged, both before 
and after the surgery, to normalise their eating behaviour and to increase their physical 
activity level. 
 
The majority (59 out of 63) of patients in the lifestyle group were referred to a rehabilitation 
centre specialising in the care of morbidly obese patients (Evjeklinikken). Using a cognitive 
approach the programme at this centre aimed to induce a weight loss of at least 10 %. Each 
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patient was motivated to increase their physical activity and to normalise their eating habits. 
The one year lifestyle programme comprised four stays at the rehabilitation centre lasting for 
either one week or four weeks (Figure 6).  
 
 Figure 6. Schedule of stays during the one year lifestyle programme at Evjeklinikken. Reproduced from Hofsø 
et al (199), no permission required. 
 
The daily programme was divided between organised physical activity (3 to 4 hours) and 
different psychosocially oriented interventions. The interventions involved individual 
consultations with a medical doctor, nutritionist, physiotherapist and a trained nurse. The 
patients also took part in group sessions focusing on the emotional aspects of sedentary 
behaviour as well as classroom lessons on topics related to nutrition, physical activity and co-
morbidities. No special diet or weight loss drugs were prescribed, but patients were 
encouraged to follow the guidelines of the Norwegian National Council of Nutrition (200) 
which recommend that the daily intake of protein, fat, carbohydrate and alcohol should 
account respectively for 10 to 20, < 30, 50 to 60 and < 5 % of energy consumed. Outside of 
these stays patients were contacted by phone once every two weeks. They were encouraged to 
self-monitor their eating habits and physical activity, as well as to visit their general 
practitioner for a consultation and weight control check once every four weeks. The 
remaining four participants were allocated to two rehabilitation centres with comparable 
intervention programmes.  
 
Paper III included all 146 of the patients who took part in the MOBIL study. Results are 
reported for the 139 completers.  
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Paper IV included a subset of 119 participants from the MOBIL study who did not use 
glucose lowering agents at baseline and who underwent an OGTT both before and after the 
interventions. Additionally, a control group of 29 normal weight (18 kg/m2 < BMI < 25 
kg/m2) persons with NGT were recruited from healthy employees at Vestfold Hospital Trust 
in Tønsberg. The controls were examined in August 2007.  
 
4.2. Clinical characteristics and definitions 
Demographic and clinical data were recorded on standardised forms. All anthropometric 
measures were made with patients in an upright position wearing light clothing and no shoes. 
Height was measured using wall mounted stadiometers; WC was measured at the level 
midway between the lowest rib margin and the iliac crest; hip circumference (HC) was 
measured at the widest level over the greater trochanters; and neck circumference (NC) was 
measured at a point just below the larynx and perpendicular to the long axis of the neck. 
Weight was measured to the nearest 0.1 kg, height to the nearest 0.5 cm and circumferences to 
the nearest 1 cm. After at least five minutes of rest, blood pressure was measured three times 
using a sphygmomanometer. The average of the second and third measurements was 
registered. 
 
In all of the papers presented in this thesis, participants have been classified into categories of 
glucose tolerance according to the WHO criteria (Table 3). Patients who used glucose 
lowering agents were classified as having type 2 diabetes. In Paper IV subjects with IFG, IGT 
and type 2 diabetes were pooled into an abnormal glucose tolerance (AGT) group. Remission 
of diabetes was defined as either partial (serum glucose levels below the diagnostic cut-off 
values and HbA1c < 6.5 %) or complete (fasting serum glucose < 5.6 mmol/l, 2 hour glucose 
< 7.8 mmol/l and HbA1c < 6.2 %) in the absence of glucose lowering agents (201). 
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In Paper III the below summarised endpoints were defined as follows; hypertension, the usage 
of anti-hypertensive drugs, systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 
90 mmHg  (202); metabolic syndrome, at least three of the following five characteristics 
(modified ATP III criteria): waist circumference ≥ 102 cm in men and ≥ 88 cm in women, 
fasting triglycerides ≥ 1.7 mmol/l, systolic blood pressure ≥ 130 mm Hg or diastolic blood 
pressure ≥ 85 mm Hg or on anti-hypertensive drugs, fasting glucose ≥ 5.6 mmol/l or on 
glucose lowering agents, or high density lipoprotein cholesterol < 1.0 mmol/l in men and <1.3 
mmol/l in women (203); albuminuria, albumin to creatinine ratio in urine ≥ 2.5 mg/mmol in 
men and  ≥ 3.5 mg/mmol in women (204); and left ventricular hypertrophy, Cornell voltage-
QRS duration product (RaVL + SV3, with 6 mm added in women) ≥ 2440 mm x ms (205,206).  
 
Dietary intake and physical activity during the preceding year were assessed through 
structured interviews performed by registered dieticians (Paper III and IV). Data were 
recorded on an optically readable food frequency questionnaire (Department of Nutrition, 
University of Oslo, Norway). Similar questionnaires have been validated using weighted 
records (207). Questionnaire data were scanned using Teleform 10.0 (Cambridge, UK). 
Dietary intake was calculated using a database assembled from official food composition 
tables (Norwegian Nutrition Council, 1995). Calculations were computer driven 
(Kostberegningssystem 6.0; University of Oslo, Norway). Time spent performing light (e.g. 
casual walking), moderate (e.g. brisk walking) and vigorous (e.g. jogging) intensity aerobic 
physical activities in periods of 10 minutes or more were recorded. Participants who 
performed 150 minutes or more per week of moderately intense aerobic physical activity were 
considered to be physically active, as were those participants who performed 60 minutes or 
more per week of vigorously intense aerobic physical activity (208).   
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Perioperative (first 30 days) and late (after 30 days) complications were recorded in each 
patient’s record file (Paper III). In addition, all medical emergencies, hospitalisations and 
gastrointestinal side-effects were reported on standardised self-report questionnaires. 
Reported symptomatic postprandial hypoglycaemia was documented by blood glucose < 2.8 
mmol/l (209,210). Complications and medical emergencies not recorded in each patient’s 
record file at our hospital were verified by reports from other institutions.  
 
In Paper II and IV, the homeostasis model assessment of insulin sensitivity (HOMA S) and β-
cell function (HOMA B) were calculated using the computer program HOMA calculator 
(211). OGTT-derived estimates of insulin sensitivity and insulin secretion were calculated in 
Paper IV: Insulin sensitivity was calculated using indices of Belfiore (212) and Stumvoll 
(213), and insulin secretion was estimated using the insulinogenic index (ΔIns30/ΔGluc30,), the 
ratio of the total area under the insulin curve to the total area under the glucose curve (total 
AUCIns/Gluc) and the Stumvoll first phase index (fist phaseest: 1283 + 1.829 x Ins30 -138.7 x 
Gluc30 + 3.772 x Ins0) (213). Furthermore, the DI, which yields a better measure of β-cell 
function (90), was calculated by multiplying HOMA S and first phaseest. Finally, proinsulin-
to-insulin (PI/I) ratios in a fasting and stimulated state (30 minutes after glucose ingestion) 
were calculated. Elevated PI/I ratios have been associated with IGT (214) and reduced insulin 
secretion (215), and these indexes may therefore indicate another aspect of beta cell function. 
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4.3. Laboratory analyses 
4.3.1. Sampling 
Blood was collected by vein puncture either in a fasting state or during an OGTT. Standard 75 
g OGTTs with blood samples taken before and 120 minutes after the glucose load were used. 
In addition, the OGTTs performed in the MOBIL study included blood sampling 30 minutes 
after the ingestion of glucose. Paper II-IV included blood samples taken solely at the 
Department of Clinical Chemistry at Vestfold Hospital Trust. Paper I included, in addition, 
glucose measurements from 348 OGTTs performed at seven other laboratories in the health 
region (Drammen, Kongsberg, Ringerike, Skien, Notodden, Arendal and Kristiansand). At 
Vestfold Hospital Trust samples clotted at room temperature and serum was separated from 
cells within either 30 minutes (OGTTs) or 2 hours (fasting samples). At the other laboratories 
in the health region glucose was analysed in serum (n = 210) or plasma (n = 64), both 
centrifuged within 60 minutes, or in capillary full blood (n = 74). All the samples at these 
laboratories were analysed at the day of the sampling. Serum samples collected at Vestfold 
Hospital Trust were either stored at -80oC (analyses performed at the Endocrine Laboratory, 
Oslo University Hospital Rikshospitalet, Paper III-IV) or -20oC (analyses performed at the 
Hormone Laboratory, Oslo University Hospital Aker, Paper II) or analysed the same day 
(analyses performed at the Department of Clinical Chemistry, Vestfold Hospital Trust, all 
Papers). Spot morning urine samples were collected and analysed the same day (Paper III). 
 
4.3.2. Biochemical assays 
At the Department of Clinical Chemistry at Vestfold Hospital Trust analyses of serum blood 
lipids and serum glucose were performed using dry reagent slide technology on the Vitros 950 
Analyzer until November 2006 and the Vitros FS 5.1 Analyzer (Ortho-Clinical Diagnostics, 
New York, NY) thereafter. Furthermore, HbA1c was analysed using high performance liquid 
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chromatography on Tosoh HLC-723 G7 (Tosoh Corporation, Tokyo, Japan), and albumin and 
creatinine in urine were analysed using Konelab 60i (Thermo Electron Corporation, Helsinki, 
Finland) until August 2008 and Vitros FS 5.1 Chemistry System thereafter.  
  
At the Endocrine Laboratory  at Oslo University Hospital Rikshospitalet serum levels of 
insulin, c-peptide, pro-insulin were measured by radio immunoassay (Insulin Coat-A-Count, 
DPC, Los Angeles, CA), whilst serum levels of C-reactive protein (R&D systems, 
Minneapolis, MN, USA) and adiponectin (R&D systems) were measured using enzyme 
immunoassays on stored samples. All samples were measured in duplicate and serial samples 
from a given individual were run at the same time (insulin, C-peptide and proinsulin). Intra- 
and inter-assay coefficients of variation (CV) were < 10 % for all assays.  
 
For measurements of glucose in serum or plasma (during OGTT) at the other laboratories in 
the health region automated instruments using either a hexokinase or a glucose oxidase 
method were used [Vitros 950 and Vitros FS 5.1 (Ortho-Clinical Diagnostics), Aeroset and 
Architect (Abbott Diagnostics), Advia 1650 and Advia 1800 (Siemens), Cobas Integra 800 
and Cobas 6000 (Roche)]. Furthermore, plasma calibrated capillary whole blood glucose 
concentrations were analyzed with portable instruments [Precision PCx (Abbott Diagnostics) 
or Accu-Check Sensor (Roche Diagnostics)].   
 
At the Hormone Laboratory at Oslo University Hospital Aker insulin was analysed in serum 
by radioimmunoassay (Linco Research Inc, St. Charles, MO, and DiaSorin, Stillwater, MN) 
within 1 week of blood sampling. The inter-assay CV for insulin was 8 %. 
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4.4. Statistics 
4.4.1. Sample size calculation for The MOBIL study 
The sample size of the MOBIL study was calculated (80 % statistical power, α-level of 0.05, 
and equal distribution to the treatment groups) based on anticipated remission rates of type 2 
diabetes and obstructive sleep apnoea. Given remission rates of type 2 diabetes of 70 % in the 
surgery group and 20 % in the lifestyle group, at least 30 subjects with type 2 diabetes were 
required. Expecting a prevalence of type 2 diabetes of 25 % and a dropout rate of 30 % from 
the screening examinations, a minimum of 172 subjects were required for screening.  
 
4.4.2. Statistical analyses 
Data are presented as mean [standard deviation (SD)], median (25th and 75th percentiles) or 
number (%) unless otherwise specified. Skewed data were transformed using natural 
logarithms to approximate normality. Unadjusted between groups differences were analysed 
using independent samples t-test, one- and two-way analysis of variance (ANOVA) or Mann-
Whitney U test for continuous variables and Chi-square or Fisher`s exact test for categorical 
data. Within-group comparisons were performed using paired samples t-test or Wilcoxon 
signed-rank test for continuous variables and McNemar test for dichotomised variables. Post- 
hoc testing was done with least significant difference tests. Correlations were calculated with 
Pearson’s correlation coefficients. For all analyses a two-tailed P < 0.05 was considered 
significant. The analyses were implemented using SPSS 16.0 (SPSS, Chicago, IL).  
 
In Paper I, ROC curve analysis was employed to determine the diagnostic accuracy of fasting 
glucose to predict a 2-hour glucose concentration ≥ 11.1 mmol/L. The diagnostic accuracy of 
the test is presented as an area under the curve (AUC) [95 % confidence interval (CI)], where 
AUC equal to 1 is the optimal value. The optimal cut off value of fasting glucose was 
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obtained using the Youden index, maximising sensitivity and specificity (sensitivity + 
specificity – 1) (216).  
 
In Paper II, logistic regression analyses were performed to study the association of 
anthropometric characteristics (continuous and standardized variables) with prevalent type 2 
diabetes. Odds ratios (ORs) per one SD increase in the anthropometric variable for type 2 
diabetes were calculated in both unadjusted and adjusted models. 
  
In Paper III and IV, adjusted between-group changes in outcome variables were assessed 
using analysis of covariance (ANCOVA). Furthermore, regression analyses were used to 
identify the effect of treatment choice and predictors of changes in outcome variables.  
 
In Paper IV, linear regression analyses were used to 1) explore a potential hyperbolic 
relationship between HOMA S and measures of insulin secretion [95% CI of the specialised 
regression coefficient (β) in the equation ln (insulin secretion) = constant + β x ln (insulin 
sensitivity) must include -1 and exclude 0]. 
 
4.5. Ethics 
4.5.1. Approvals 
Written informed consent was provided by all participants. The Morbid Obesity Biobank 
Registry has been approved by the regional ethics committee of what was formerly the 
Southern Norway Regional Health Authority (Reference number S-05175), the Norwegian 
Social Science Data Service (Reference number 14029) and the former The Directorate for 
Health and Social Affairs (Reference number 06/530). The MOBIL study was approved by 
the regional ethics committee of what was formerly the Southern Norway Regional Health 
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Authority and was registered in the ClinicalTrials.gov-registry under the unique trial number 
NCT00273104.  
 
4.5.2. Funding  
This work has been supported by unrestricted grants from Novo Nordisk A/S, Vestfold 
Hospital Trust and South-Eastern Norway Regional Health Authority to DH. One of the co-
authors of Paper III (TIK) is one of the founders of Evjeklinikken A/S and is a former board 
member (until November 2008) and stockholder (until August 2009). He is now a PhD-
student at the Morbid Obesity Centre and is supported financially by Evjeklinikken A/S. All 
the other authors declare that there is no conflict of interest that could be perceived as 
prejudicing the impartiality of the research reported. The funders had no role in the study 
design, data collection and analysis, decision to publish or preparation of the manuscript. 
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5. Results 
Paper I 
The primary objective of this study was to assess the effectiveness of fasting glucose to detect 
undiagnosed diabetes in morbidly obese subjects. Among the 1 253 participants 46 % had 
NGT, 8 % had isolated IFG, 16 % had IGT and 31 % had type 2 diabetes of which those with 
screen-detected diabetes accounted for 8 percentage points. The ROC curve analysis showed 
that fasting glucose was highly accurate in predicting a diabetic 2-hour glucose concentration 
in subjects with unknown glucose tolerance status (n = 670); AUC (95 % CI) 0.93 (0.89-
0.98). The optimal fasting glucose cut off value was 6.5 mmol/l with corresponding 
sensitivity and specificity values of 88 % and 89 %, respectively. 
 
Among patients with screen-detected diabetes 80 % (53 out of 66) had elevated fasting 
glucose whereas only 20 % (13 out of 66) had isolated elevated 2-hour glucose. Performing 
an OGTT in subjects with fasting glucose between 6.1 and 6.9 mmol/l would identify 77 % 
(10 out of 13) of those with isolated elevated 2-hour glucose. Taken together, 95 % [80 % (53 
out of 66) by fasting glucose and 15 % (10 out of 66) by 2-hour glucose] of all subjects with 
unknown type 2 diabetes would be identified if subjects with a fasting glucose level between 
6.1 and 6.9 mmol/l underwent a confirmatory OGTT.  
 
Paper II 
This paper reports the relationship between various measurements of obesity and type 2 
diabetes in subjects with BMI ≥ 40 kg/m2. Out of 1 003 subjects 267 (27 %) had type 2 
diabetes. The regression analyses showed that WC, WHR and NC were independently and 
positively associated with type 2 diabetes. By contrast, HC was negatively associated with 
type 2 diabetes, and no association between BMI and type 2 diabetes was found.  
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Paper III 
In this paper we compared the effect of bariatric surgery (n = 80) and intensive lifestyle 
intervention (n = 66) on type 2 diabetes and obesity-related cardiovascular risk factors. 
Among the 76 completers in the surgery group and the 63 completers in the lifestyle group 
mean (SD) one year weight loss was 30 (8) % and 8 (9) %, respectively. Although both 
treatment groups experienced improvements in nearly all measures of obesity, blood 
pressures, lipids, glucose metabolism and inflammatory markers, the improvements were 
significantly greater after surgical treatment than after lifestyle intervention. Multi-adjusted 
regression analyses showed that weight loss, but not treatment choice, was significantly 
associated with reduction in HbA1c (P = 0.008) and systolic blood pressure (P = 0.001).  
 
Remission rates of type 2 diabetes and hypertension were significantly higher in the surgery 
group than the lifestyle intervention group; 70 % versus 33 %, P = 0.027; and 49 % versus 23 
%, P = 0.016. No usage of glucose lowering agents and anti-hypertensive drugs at baseline 
were, independent of percentage weight change and treatment choice, associated with 
remission of type 2 diabetes (P = 0.023) and hypertension (P < 0.001).  
 
The surgery group experienced a significantly greater reduction in the prevalence of 
metabolic syndrome (76 % to 18 % versus 70 % to 48 %, P < 0.001), albuminuria (15 % to 6 
% versus 13 % to 19 %, P = 0.012) and electrocardiographic left ventricular hypertrophy (17 
% to 4 % versus 11 % to 8 %, P = 0.046) than the lifestyle group. There was a greater increase 
in the physical activity level of the lifestyle group than the surgery group (P = 0.022). 
 
Overall, complications occurred more often after gastric bypass than after lifestyle 
intervention. Gastrointestinal symptoms developed more frequently after gastric bypass than 
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lifestyle intervention, 48 % versus 7 %, P < 0.001. Five surgically treated patients reported 
symptomatic postprandial hypoglycaemia. There were no deaths. 
  
Paper IV 
In this paper we compared the effect of intensive lifestyle intervention (n = 55) and Roux-en-
Y gastric bypass surgery (n = 64) on beta cell function. The patients were classified as having 
either NGT or AGT. In addition, 29 normal weight subjects with NGT served as controls. 
Insulin secretion relative to insulin sensitivity (DI) increased more after surgical treatment 
than after lifestyle intervention (P < 0.001), with no effect of glucose tolerance status at 
baseline (P = 0.323). The reduction in stimulated PI/I ratio was greatest after surgical 
treatment (P < 0.001) and was most pronounced among those with AGT (P < 0.001). Notably, 
at one year DI was higher and stimulated PI/I ratio lower in surgically treated patients with 
NGT at baseline than in the NGT controls (P < 0.001 and P = 0.027, respectively). 
 
Multiple linear regression analyses showed that both surgical treatment and weight reduction 
independently predicted increase in DI (β = 0.337, P = 0.008, and β = -0.329, P = 0.008, 
respectively). By contrast, only surgical treatment independently predicted reduction in 
stimulated PI/I ratio (β = -0.339, P = 0.022).  
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6. Discussion 
The main results of the papers included in this thesis are: 1) Fasting glucose identifies four out 
of five morbidly obese subjects with unknown type 2 diabetes. 2) Measures of central obesity, 
and not BMI, are associated with type 2 diabetes in extremely obese patients. 3) Gastric 
bypass surgery improves obesity-related cardiovascular risk factors and beta cell function to a 
significantly greater extent than intensive lifestyle intervention. This section of the thesis will 
discuss methodological aspects, compare the results with other studies, state possible 
implications and suggest topics for future research.  
 
6.1. Methodological considerations 
The main limitations and strengths of the studies are summarised in Table 6. 
 
Table 6. Main limitations and strengths of the studies 
Paper  Limitations Strengths 
Paper I Missing OGTTs  
Few patients with screen-detected diabetes 
Clinically relevant 
Paper II Cross-sectional design Large study sample 
Paper III-IV Non-randomised design Controlled study 
Few drop-outs 
Paper IV Non-validated indices of beta cell function Frequent samples OGTTs   
 
6.1.1. Study designs and statistics 
Patients included in the studies presented in this thesis were recruited from a tertiary health 
care centre exclusively treating morbidly obese patients. Therefore, it is possible that the 
referral of patients to our centre might have introduced a sampling selection bias (tendency of 
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a sample to exclude or include some members of the sampling universe). Moreover, as the 
definition of morbid obesity is not solely dependent upon BMI but also takes into account 
obesity related co-morbidities, the prevalence of obesity related co-morbidities among 
patients with BMI between 35 and 40 kg/m2 may have be especially high and differ from the 
general population. This may have reduced the external validity of the results of the studies 
reported in this thesis. Caution should therefore be used when generalising the results to all 
grade II and III obese subjects.  
 
No adjustments for multiple comparisons were made in any of the studies. However, most of 
the between group differences were highly significant and adjustments for multiple 
comparisons would probably not have influenced the main conclusions of the studies. 
 
Paper I 
The high proportion of missing OGTTs in Paper I may have resulted in a systematic 
difference (selection bias) between subjects who did and did not perform the OGTT. Despite 
similar fasting glucose values in the two groups, we cannot exclude that important differences 
between these groups may have influenced the results. This may have reduced the internal 
validity of this paper.  
 
The sample size was relatively large (n = 1 253). However, only 66 subjects had screen-
detected diabetes and only a very few (n = 13) had an isolated diabetic 2 hour glucose 
concentration. Accordingly, the glucose values of the subjects with screen-detected diabetes 
had a major impact on the results. Small changes in glucose values could potentially have 
resulted in relatively large changes in the percentages reported. This should be kept in mind 
when evaluating the accuracy of the results of the ROC curve analysis in this subgroup.   
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Paper II 
As mentioned, the prevalence of obesity-related conditions may, due to the definition of 
morbid obesity, be artificially high in subjects with BMI between 35 and 40 kg/m2. To avoid 
sampling selection bias, only subjects with BMI ≥ 40 kg/m2 were considered for inclusion in 
this study. As this study had a cross-sectional design it cannot be used to identify causal 
relationships. Therefore, we cannot, based upon the results in this study, determine whether 
central obesity causes type 2 diabetes or vice versa.  
 
The sample size was relatively large (n = 1 003). Still, we cannot exclude the possibility that 
the lack of association between BMI and waist-to-height ratio and type 2 diabetes may be due 
to limited power (type 2 errors). 
 
Paper III and IV 
Random allocation of different treatment strategies to study participants is preferable when 
conducting clinical trials. The most important advantage of this design is that it enhances the 
internal validity (difference in outcomes is related to the intervention) of the study by 
minimising selection bias and confounders. According to Norwegian guidelines, treatment 
seeking morbidly obese subjects should be offered either conservative or surgical therapy 
(217). For this reason we considered it unethical to assign patients to surgery if they qualified 
for a lifestyle intervention programme and preferred this course of treatment to surgery. This 
stance also held vice-versa. The MOBIL study therefore had a non-randomised design. 
Although not randomised, the MOBIL study is one of a few studies that actually compare the 
effects of bariatric surgery and lifestyle intervention on obesity-related health outcomes. 
Importantly, some baseline differences were observed (the surgery group was younger and 
heavier). These factors could influence the outcomes and are therefore potential confounding 
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factors. In an attempt to cope with these differences, adjustments for baseline differences and 
changes in relevant medications were made when the effects of treatment choice were 
calculated. Still, we cannot exclude the possibility that factors not included in the statistical 
analyses could have influenced the results.  
 
Drop-outs can also result in selection biases. However, due to the low drop-out rate in the 
MOBIL study, it is not likely that this has influenced the result significantly. This is supported 
by the last observation carried forward analyses in Paper III which showed that the main 
conclusions of the study were not altered by these analyses. 
 
All patients in the MOBIL study followed routine care pathways and were given the same 
priority for treatment as other patients. Due to a waiting list for bariatric surgery at our 
institution, the time from inclusion to intervention was significantly longer for the surgery 
group than the lifestyle group. Since no re-registrations were made immediately before the 
start of treatment, we cannot exclude the possibility that changes in weight, medications and 
metabolic variables occurred prior to, and not after, the interventions. 
 
The sample size of the MOBIL study was calculated based on expected remission rates of 
type 2 diabetes (and obstructive sleep apnoea). Despite a higher remission rate of type 2 
diabetes in the lifestyle group than expected, significant differences between the groups were 
observed due to a higher number of diabetic subjects than originally anticipated.  
 
6.1.2. Data quality 
All the anthropometric measures were performed in a standard manner. Despite standardised 
measuring techniques, we cannot exclude the possibility that inter-individual differences may 
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have affected the results. It should also be noted that measuring body circumferences in 
morbidly obese subjects is challenging and may limit, due to inaccurate measures, their usage 
in predicting cardiovascular risk (218).  
 
Blood glucose measurements may, due to biological and analytic variability, vary 
considerably from day-to-day (219). For these reasons, the diagnoses of type 2 diabetes 
should be based on repeated measurements (63). In the studies included in this thesis serum 
glucose was measured at one occasion, and this may have overestimated the number of 
diabetic patients not using hypoglycaemic drugs. However, in epidemiological studies one 
glucose measurement is sufficient for the diagnosis of type 2 diabetes (220). Similarly, in 
Paper III blood pressure and albumin and creatinine in urine were measured only once.  
 
Paper I included glucose measurements from OGTTs performed in eight laboratories using 
different analysing methods. In addition, glucose was measured in plasma, serum and 
capillary blood, and the time from sampling to analysing differed slightly (30 to 60 minutes) 
between the laboratories. Glucose concentration in uncentrifuged blood declines 
approximately 0.3 to 0.6 mmol/l per hour due to glycolysis (221,222). This could potentially 
have resulted in a selection bias. However, the fact that there was no significant (P = 0.109) 
difference in fasting glucose between the laboratories indicates that the impact of including 
glucose measurements from different laboratories was minor.  
 
In Paper III left ventricular hypertrophy was identified based on electrocardiographic 
characteristics. The Cornell voltage criteria was used since this index is less influenced by the 
presence of obesity (223) and weight reduction (224) than other more commonly used indices. 
Moreover, regression of electrocardiographic left ventricular hypertrophy identified by the 
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Cornell voltage criteria is known to predict regression of echocardiographic left ventricular 
hypertrophy (225). However, the Cornell voltage criteria only has a 54 % sensitivity for 
detecting left ventricular hypertrophy (226) and imaging techniques for the estimation of 
ventricle mass would therefore have been preferable. Nevertheless, electrocardiographic left 
ventricular hypertrophy is a strong predictor of cardiovascular mortality in both subjects with 
hypertension and those without (227). 
 
In Paper III dietary intake and physical activity were assessed through structured interviews 
performed by registered dieticians. Obese subjects are known to under-report food intake 
(228). Consequently, the actual energy intake is likely to be slightly higher than reported. 
Furthermore, based on self-reported physical activity levels patients were categorised as being 
either physically active or inactive. Similarly, the use of self-reported data may have reduced 
the internal validity of the results. The use of use accelerometers (229) or physical tests would 
have been preferable, but also more demanding, and were therefore not performed. 
 
In Paper IV OGTT-derived indices were used for the estimation of beta cell function. The 
insulin secretion index included in the disposition index (first phaseest) has been validated 
against hyperglycaemic clamp (213). The usage of a disposition index requires a hyperbolic 
association between insulin secretion and insulin sensitivity (89). The combination of HOMA 
S and first phaseest showed a non-linear relationship in subjects with NGT but did not fully 
satisfy the criteria for a hyperbolic relationship (Figure 7A). This is a limitation of the study 
and should be kept in mind when interpreting the results. In addition, none of the indices have 
been validated in post-bypass patients. The rearrangement of the intestinal tract seems to 
result in relatively enhanced glucose absorption with a prompter increase in serum glucose 
levels (Figure 7B). This may in turn affect serum insulin and proinsulin levels which are all 
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used for the calculation of these indices. It is therefore possible that changes in glucose 
absorption post-surgery may result in changes in insulin and proinsulin secretion that are not 
solely related to improved beta cell function. Indeed, one study has shown that the DI from 
OGTT data increased more than the intravenous glucose tolerance test derived DI after 
bariatric surgery (230).  
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Figure 7. A The association between insulin secretion (first phaseest) and Homa S in 94 subjects with normal 
glucose tolerance showed a non-linear relationship that was close to hyperbolic (ideally the 95 % CI of β should 
have included -1). B Mean (95 % CI) serum glucose levels during the OGTT before (straight line) and after 
(dashed line) gastric bypass surgery in 64 morbidly obese subjects. Post surgery there was a prompter rise in 
glucose 30 minutes after the glucose load. Figures are based on data from Paper IV (231).  
 
6.1.3. Ethnicity 
The great majority of the study population was of Europoid origin, meaning that the results of 
this study cannot be generalised to include other ethnic groups. 
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6.2. In context with other studies 
6.2.1. Screening for type 2 diabetes in morbidly obese subjects 
Paper I showed that in morbidly obese patients fasting glucose ≥ 7.0 mmol/l identified 80 % 
of all subjects with unknown diabetes. In addition, we verified an extremely high prevalence 
of type 2 diabetes (31 %) in morbidly obese subjects (21).  
 
A two step screening strategy was explored using fasting plasma glucose as a screening 
variable followed by an OGTT in subjects with fasting plasma glucose below the diagnostic 
level for type 2 diabetes. The results showed that fasting plasma glucose ≥ 7.0 mmol/l 
identified 80 % of all subjects with unknown diabetes (Figure 9). This is to some extent 
higher than reported in several lager population based studies (45 to 76 %) (232-236). 
However, previous reports have shown that obese and young people are more likely to be 
diagnosed by fasting plasma glucose than 2 hour plasma glucose (233,235,236). The 
relatively low age and the extreme obesity of participants in this study are probably the main 
reasons for the high proportion diagnosed by fasting plasma glucose. Indeed, two studies 
including surveys from southern hemisphere islands and from European populations reported 
the sensitivity of fasting plasma glucose to detect diabetes in obese subjects to be comparable 
with our findings, 78 % and 84 %, respectively (233,237). Moreover, increasing fasting 
plasma glucose levels up to the WHOs recommended cut-off value of 6.1 mmol/l only slightly 
reduced the sensitivity of fasting plasma glucose for detecting subjects with a diabetic 2 hour 
plasma glucose concentration. However, the proportion of subjects needing an OGTT was 
reduced substantially. If a confirmatory OGTT was used only if fasting plasma glucose was 
between 6.1and 6.9 mmol/l, 21 % of the population with unknown glucose tolerance would 
need an OGTT, and this strategy would identify 95 % of all subjects with unknown diabetes. 
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The same approach in a European population identified 82 % of the people with diabetes after 
testing 12 % of the population. 
 
 
Figure 9. Overlap between screen-detected diabetic subjects (n = 66) diagnosed by a fasting plasma glucose 
(fPG) ≥ 7.0 mmol/L or a 2 hour plasma glucose (2hPG) ≥ 11.1 mmol/L.  Reproduced from Hofsø et al. (238) 
with permission. 
 
The results of Paper I indicate that fasting glucose followed by an OGTT in subjects at risk is 
an effective strategy for detecting undiagnosed type 2 diabetes. However, it is still not clear 
how diabetes screening should be performed and what the benefits of pro-active screening 
strategies would be. Interestingly, unpublished data from the ADDITION trial show that in 
patients with screen-detected diabetes intensive multifactorial treatment was not significantly 
better than routine care in preventing cardiovascular events (239). Partly in contrast with these 
findings, poor long-term glycaemic control during 20 years follow-up was associated with an 
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increased risk of death by ischemic heart disease in subjects with newly diagnosed diabetes 
(240). 
 
6.2.2. Anthropometric measures and type 2 diabetes in extremely obese subjects 
Paper II suggests that central, but not overall obesity is associated with prevalent type 2 
diabetes in extremely obese individuals (Figure 8).  
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Figure 8. Odds ratios (vertical bars, 95% CIs) for having type 2 diabetes per one standard deviation (SD) 
increase in the anthropometric variable 1 003 extremely obese subjects. One SD: BMI, 5.5 kg/m2; waist 
circumference (WC), 13.7 cm; hip circumference (HC), 11.5 cm; waist-to-hip ratio (WHR), 0.10; waist-to-height 
ratio (WHtR), 0.07 and neck circumference (NC), 4.5 cm. Reproduced from Hofsø et al. (241) with permission. 
 
The lack of association between BMI and type 2 diabetes is in contrast with several previous 
reports in normal weight to moderately obese patients (13-19,242,243). This may indicate that 
increasing BMI levels above 40 kg/m2 do not necessarily translate into higher odds of having 
type 2 diabetes. Furthermore, our findings suggest that measures of central obesity may be 
useful predictors for type 2 diabetes in extremely obese subjects, as has been previously 
reported in less obese subjects (13-19,242). A 1 SD increase in WHR (0.10) and WC (14 cm) 
was associated with about 50 % and 30 % increased odds of having type 2 diabetes. In line 
57 
with some (13,18,242), but not all (14-17,19) reports, our data suggest that WHR may be a 
better predictor of type 2 diabetes than WC. In addition, the inverse association between HC 
and type 2 diabetes was strengthened after adjusting for confounding factors, as shown 
previously (13,18,242). Finally, previous reports have shown an association between NC and 
type 2 diabetes in white women from Canada and the US (13). Moreover, NC has been shown 
to correlate with both glucose and insulin in severely obese subjects (244). Our results extend 
these observations, showing an independent association between NC and type 2 diabetes in 
extremely obese individuals. The inclusion of HOMA S in the regression analyses attenuated 
the associations between the anthropometric characteristics and type 2 diabetes. This finding 
corresponds with results reported by Haffner et al. (243), suggesting that these associations 
might be mediated by insulin resistance.  
 
6.2.3. Obesity-related cardiovascular risk factor after weight loss 
The one year non-randomised controlled MOBIL study (Paper III) showed that obesity-
related cardiovascular risk factors improved after both gastric bypass surgery and intensive 
lifestyle intervention. Importantly, the improvements were greater after surgical treatment.  
 
This study was planned and initiated in 2005. By that time the beneficial effect of weight loss 
on obesity-associated medical complications was well known (122,124,245). Furthermore, 
two drugs available on the European market had proven effective in inducing and maintaining 
weight loss and in improving metabolic conditions (106-109). Similarly, bariatric surgery had 
demonstrated substantial weight loss and positive effects on numerous obesity related 
comorbidities (149-152,154,157,159,160,246). However, with the exception of the case-
controlled SOS study (154), none of the studies included medically treated controls. The aim 
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of the MOBIL study was therefore to compare the effect of gastric bypass surgery and a 
comprehensive lifestyle intervention programme on several obesity related health conditions. 
 
Several reports with great relevance to the field of obesity treatment have been published 
since the MOBIL study was initiated: 
 
Bariatric surgery versus lifestyle intervention 
 Three randomised controlled clinical trials from an Australian group comparing 
laparoscopic adjustable gastric banding and conventional therapy have shown that 
gastric banding results in greater weight loss and resolves type 2 diabetes and 
metabolic syndrome more effectively than conventional therapy (155,156,158). 
 One non-randomised controlled Norwegian study showed that gastric bypass surgery 
resulted in greater weight loss than comprehensive lifestyle intervention programmes. 
However, the improvements in metabolic risk factors did not differ between the study 
groups (127).  
Bariatric surgery 
 Mortality data from the SOS study and a large retrospective cohort study indicate that 
bariatric surgery reduces mortality (171,172). 
 A systematic review and meta-analysis by Henry Buchwald clearly demonstrates 
reduced 30-days mortality after bariatric surgery (173). 
Medical treatment of obesity 
 The randomised LookAHEAD trial has shown that in overweight and obese subjects 
with type 2 diabetes a mean weight loss of 6 % can be sustained for four years by 
combining diet modification and physical activity (125,126). 
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 Two US studies including extremely obese subjects reported 15 to 20 % weight loss 
after six months (129,131) and 10 % weight loss after 2 year by including low calorie 
diets in a lifestyle intervention programme (131).   
 Due to their serious side-effects, sibutramine and rimonabant have been withdrawn 
from the European market (118,120). 
 
In light of what was known when the MOBIL study was planned and new knowledge 
published the last five years,  our results confirm that gastric bypass surgery results in greater 
weight reduction (30 % versus 8 %) and higher remission rates of type 2 diabetes and 
hypertension than intensive lifestyle intervention (Figure 10). Furthermore, we verify that 
modest weight reduction after intensive lifestyle intervention also improved several obesity-
related cardiovascular risk factors. Lower mortality rates after bariatric surgery, as reported by 
Sjöström et al. and Adams et al., indicate that weight reduction may translate into increased 
survival (171,172). In the study by Adams et al. mortality caused by coronary artery disease 
was decreased significantly. Due to the lack of clinical data in this study it is impossible to 
estimate the potential effect of improvements in obesity-related cardiovascular risk factors on 
cardiovascular mortality. However, meta-analyses of intervention trials have shown that 1 
mmol/l reduction in low density lipoprotein cholesterol, 10/5 mmHg reduction in blood 
pressure and 0.9 % reduction in HbA1c is associated with a reduction in fatal and non-fatal 
myocardial infarction and sudden death of 23, 22 and 9.7 %, respectively (247). Based on 
these figures and our own results (reduction in low density lipoprotein cholesterol, blood 
pressure and HbA1c after surgery: 1.0 mmol/l, 14/12 mmHg and 0.4 %, respectively) we 
might speculate that the reduction in death caused by coronary artery disease after bariatric 
surgery is most likely mediated by the improvements in cholesterol and blood pressure and to 
a lesser extent by the improved glycaemic control.  
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 Figure 10. Remission of type 2 diabetes and hypertension at one year correlated to percentage weight change in 
individuals treated with gastric bypass surgery or intensive lifestyle intervention. Red triangles represent patients 
treated with gastric bypass, whilst blue circles represent subjects who chose lifestyle intervention. Open 
triangles/circles denote complete remission of type 2 diabetes and remission of hypertension, half filled 
triangles/circles denotes partial remission of type 2 diabetes, and filled triangles/circles denote no remission. 
Mean percentage weight changes (black diamonds) within the groups are shown with bars extending from the 
diamonds representing 95% CI. Odds ratios (OR) were calculated using logistic regression analyses. Combined 
(partial and complete) remission of type 2 diabetes was used in the analysis. Reproduced from Hofsø et al (199), 
no permission required. 
 
Physical activity level increased slightly more in the lifestyle group than in the surgery group. 
Increase in physical fitness has been shown to reduce mortality (248,249). If increased 
physical activity translates into improved physical fitness, this could potentially have a 
positive effect on mortality rates.   
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Lower mean weight reduction in the MOBIL study than in two Scandinavian studies 
(127,128) also using specialised rehabilitation centres may be due to the short duration of stay 
(7 weeks versus 16 to 21 weeks) at the centre in the present study. These findings may 
indicate that weight loss is related to the intensity and duration of the lifestyle intervention 
programme. The programme at Evjeklinikken focused mainly on physical activity and no 
special diet or weight loss drugs were prescribed routinely. However, the patients were 
encouraged to follow the guidelines of the Norwegian National Council of Nutrition (200). 
Systematic use of low calorie diets and weight loss drugs could potentially have increased the 
weight loss.  
 
6.2.4. Beta cell function after weight loss 
Gastric bypass surgery improved beta cell function to a significantly greater extent than 
intensive lifestyle intervention. 
 
As is reported in most intervention studies, our data indicate improved beta cell function after 
lifestyle intervention (250-252) and bariatric surgery (230,253,254). Figure 11 shows that the 
first phaseest in relation to HOMA S shifted to the right after treatment in both the surgery and 
lifestyle groups. These findings are consistent with increased insulin secretion relative to 
insulin sensitivity after both interventions. However, the DI increased significantly more after 
surgical treatment than lifestyle intervention in both glucose tolerance groups 
 
In contrast, insulin secretory capacity to intravenous glucose in subjects with NGT or IGT did 
not change one year after gastric bypass when accounting for prevailing insulin sensitivity 
(255). This discrepancy may illustrate the impact of different techniques for calculating DI 
(intra venous versus per oral) as discussed previously (230). Since improvement in DI was 
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independently associated with weight reduction, a greater weight loss in the surgery groups 
than in the lifestyle groups could explain some of the differences. However, it should be noted 
that surgical treatment also independently predicted improvements in DI and that 
improvements in stimulated PI/I ratio was associated with surgical treatment and not with 
weight reduction. The latter findings indicate that the improvements in beta cell function may 
be partly related to the surgical procedure per se and not only to weight reduction. 
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Figure 2. Mean HOMA-S plotted against first phaseest in controls and morbidly obese subjects with normal 
glucose tolerance (A) and abnormal glucose tolerance (B) before and one year after gastric bypass and lifestyle 
intervention. The curve represents the regression line of the natural logarithm of estimated insulin secretion as a 
linear function of the natural logarithm of estimated insulin sensitivity for all participants with normal glucose 
tolerance at baseline. Based on data from Paper IV (231). 
 
One year after surgery, there was a high prevalence (7 %) of post-challenge hypoglycaemia. 
As demonstrated in this and previous studies, excessive insulin secretion may occur after 
gastric bypass (183,254). Rapid absorption of glucose after bypass surgery may, as discussed 
previously, in turn stimulate insulin secretion and thereby contribute to the observed 
hyperinsulinaemia. However, it is also very likely that other factors are involved, and a few 
publications have recently addressed this phenomenon (182,183). Some researchers argue that 
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post-gastric bypass hyperinsulinaemia may be explained by the increase in gut hormones such 
as glucagon-like peptide 1 and gastric inhibitory peptide which follow the rearrangement of 
the intestine (183,254). Alternatively, but not mutually exclusive, pathologic overgrowth of 
pancreatic beta cells after bypass surgery, possibly stimulated by glucagon-like peptide 1 may 
result in hypersecretion of insulin (182). Interestingly, a large Swedish nationwide cohort 
study showed that patients who had undergone gastric bypass had an increased risk of 
hospitalisation for hypoglycaemia and related diagnoses (256). This underscores the clinical 
relevance of this phenomenon. Compared to the Swedish study, we report a much higher 
incidence of symptomatic post-challenge hypoglycaemia. This may indicate that the problems 
associated with post-gastric bypass hypoglycaemia are under-diagnosed. 
 
6.3. Clinical implications 
A two-step screening approach including fasting glucose followed by an OGTT in subjects 
with IFG is an effective screening strategy and identifies 95 % of all morbidly obese subjects 
with unknown type 2 diabetes. This screening strategy could be used at institutions treating 
morbidly obese patients. 
 
Measures of central obesity seem to be more strongly associated with type 2 diabetes than 
general obesity in extremely obese subjects. These findings highlight the impact of abdominal 
fat accumulation on type 2 diabetes. However, due to the high prevalence of type 2 diabetes in 
this population, all subjects should, independent of body composition, be tested for type 2 
diabetes.  
 
Although gastric bypass surgery is more effective than lifestyle intervention in terms of 
improving obesity-related cardiovascular risk factors and beta cell function, both treatments 
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should, due to the safety concerns associated with the surgical treatment, be offered to all 
treatment seeking morbidly obese subjects. The MOBIL study also demonstrates the 
limitations of both the surgical and medical treatment of obesity. From a societal perspective 
the prevention of obesity is probably just as important as the treatment of obesity. It is 
therefore of paramount importance that changes are made within society that promote healthy 
living (1,257).  
 
6.4. Topics for future research 
The beneficial effects of screening for type 2 diabetes are not fully known. The effects of 
early detection and treatment of diabetes on micro- and macro-vascular outcomes and 
mortality are therefore relevant topics for future studies. In addition, the validation of 
alternative screening strategies (questionnaires and HbA1c) for the detection of type 2 
diabetes is also a potential research avenue.  
 
Positive effects on type 2 diabetes and obesity-related cardiovascular risk factors after 
bariatric surgery and lifestyle intervention have been documented. However, several questions 
remain unanswered: 1) Are the improvements after gastric bypass surgery related only to 
weight reduction or is there an independent effect of the gastrointestinal rearrangement? 2) 
Can bariatric procedures other than gastric bypass surgery yield similar or better results with 
lower complication rates and fewer side-effects? 3) How can lifestyle interventions be 
optimised? 4) How can the subjects who will benefit the most from the different treatments be 
identified? These are all relevant questions that should be addressed in future mechanistic and 
clinical studies. 
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The mechanism by which weight-loss after gastric bypass surgery and lifestyle intervention 
improves beta cell function is not fully understood. Future studies addressing this question 
should be longitudinal, use both intravenous and oral techniques for the estimation of beta cell 
function and include gut hormones. 
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7. Conclusions 
When screening for type 2 diabetes in morbidly obese subjects a two-step screening approach, 
fasting glucose followed by a supplemental OGTT in selected subjects, identified the great 
majority of subjects with undiagnosed type 2 diabetes.  
 
Measures of central obesity, and not BMI, were independently associated with type 2 diabetes 
in extremely obese subjects. 
 
Type 2 diabetes and obesity-related cardiovascular risk factors improved after both gastric 
bypass surgery and intensive lifestyle intervention. However, the improvements were greatest 
in those patients treated with gastric bypass.  
 
Gastric bypass surgery improved beta cell function to a significantly greater extent than 
intensive lifestyle intervention. Supra-physiological insulin secretion and proinsulin 
processing may indicate excessive beta cell function after gastric bypass surgery.   
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Abstract
Objective: Weight reduction improves several obesity-related health conditions. We aimed to compare
the effect of bariatric surgery and comprehensive lifestyle intervention on type 2 diabetes and obesity-
related cardiovascular risk factors.
Design: One-year controlled clinical trial (ClinicalTrials.gov identiﬁer NCT00273104).
Methods: Morbidly obese subjects (19–66 years, mean (S.D.) body mass index 45.1 kg/m2 (5.6), 103
women) were treated with either Roux-en-Y gastric bypass surgery (nZ80) or intensive lifestyle
intervention at a rehabilitation centre (nZ66). The dropout rate within both groups was 5%.
Results: Among the 76 completers in the surgery group and the 63 completers in the lifestyle group,
mean (S.D.) 1-year weight loss was 30% (8) and 8% (9) respectively. Beneﬁcial effects on glucose
metabolism, blood pressure, lipids and low-grade inﬂammation were observed in both groups.
Remission rates of type 2 diabetes and hypertension were signiﬁcantly higher in the surgery group
than the lifestyle intervention group; 70 vs 33%, PZ0.027, and 49 vs 23%, PZ0.016.
The improvements in glycaemic control and blood pressure were mediated by weight reduction.
The surgery group experienced a signiﬁcantly greater reduction in the prevalence of metabolic
syndrome, albuminuria and electrocardiographic left ventricular hypertrophy than the lifestyle group.
Gastrointestinal symptoms and symptomatic postprandial hypoglycaemia developed more frequently
after gastric bypass surgery than after lifestyle intervention. There were no deaths.
Conclusions: Type 2 diabetes and obesity-related cardiovascular risk factors were improved after both
treatment strategies. However, the improvements were greatest in those patients treated with gastric
bypass surgery.
European Journal of Endocrinology 163 735–745
Introduction
Obesity (body mass index (BMI) R30 kg/m2) and its
metabolic consequences, hyperglycaemia and high
blood pressure, are major risk factors of cardiovascular
morbidity and mortality (1, 2). Alongside tobacco usage
and physical inactivity they represent the ﬁve leading
global risks to mortality (3). In addition, several
other cardiovascular risk factors, such as metabolic
syndrome, albuminuria, left ventricular hypertrophy
and low-grade inﬂammation, are all closely associated
with obesity (4–7).
As the prevalence of obesity, and especially extreme
obesity, has dramatically increased in the last few
decades (8), so too has the usage of bariatric surgery
to treat morbid obesity (BMIR40 kg/m2 or BMI
R35 kg/m2 with at least one obesity-related comorbid-
ity) (9). Currently, the most commonly performed
bariatric procedure worldwide is the Roux-en-Y gastric
bypass surgery (9). Several studies have documented
how obesity surgery allows for large weight reduction
and improvements in obesity-related conditions
(10–15). Furthermore, comprehensive lifestyle inter-
vention programmes have also demonstrated, although
to a lesser extent, signiﬁcant short-term weight
reduction and improvements in cardiovascular risk
factors in moderate to severely obese subjects (16–19).
Importantly, increased physical activity, a pivotal
component of all lifestyle intervention programmes,
has been shown to have positive metabolic effects
beyond weight reduction (20). However, only two
controlled clinical trials have compared the effect of
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bariatric surgery and conventional therapy on the
resolution of diabetes and cardiovascular risk factors
(10, 11). In these studies, the average weight loss in
the non-surgically treated groups was negligible. Not
all morbidly obese subjects are suitable for bariatric
surgery and therefore non-surgical treatment alter-
natives are needed.
The objective of this 1-year non-randomised
controlled clinical trial was to compare the effect of
Roux-en-Y gastric bypass surgery and a comprehensive
lifestyle intervention programme on type 2 diabetes and
obesity-related cardiovascular risk factors.
Subjects and methods
Study design and participants
This study was conducted at a public tertiary care
centre at Vestfold Hospital Trust, Tønsberg, Norway.
Although preferable when conducting a clinical trial,
we did not ﬁnd randomisation to be appropriate.
According to Norwegian guidelines, treatment seeking
morbidly obese subjects should be offered either
conservative or surgical therapy (21). We therefore
considered it unethical to assign patients to surgery if
they qualiﬁed for a lifestyle intervention programme
and preferred this course of treatment to surgery.
This stance also held vice versa.
In order to participate in the non-randomised
controlled morbid obesity treatment, bariatric surgery
versus intensive lifestyle intervention (MOBIL) study
consecutive patients were pre-screened between
December 2005 and May 2006 (Fig. 1). The MOBIL
study aimed to address changes in several health
outcomes related to obesity. Clinical and laboratory
examinations were performed during pre-screening.
Furthermore, patients who satisﬁed the criteria for
bariatric surgery (22) and wanted either gastric bypass
surgery or intensive lifestyle intervention were referred
to a screening examination which included an oral
glucose tolerance test, a somnography, pulmonary
function tests, quality of life questionnaires and a
structured dietary interview. All patients underwent a
thorough assessment conducted by a multidisciplinary
team consisting of an internist, a dietician and, in cases
of surgery, a surgeon before treatment. These health
professionals provided complete information about the
possible risks and beneﬁts of an operation and
encouraged patients to incorporate their own values
and preferences into the decision-making process. Each
patient and their physician agreed together upon the
most appropriate choice of therapy. The elapsed period
of time between the pre-screening examination and
the screening examination was 18 weeks (11); this did
not differ signiﬁcantly between the study groups
(PZ0.063). By contrast, the time between the
screening examination and either the date of surgery
or the start of lifestyle intervention was signiﬁcantly
longer in the surgery group than in the lifestyle group,
65 weeks (14) versus 19 weeks (15) (P!0.001).
One-year follow-up was completed by June 2009. This
article reports changes in weight, glucose- and lipid
metabolisms, blood pressure, albuminuria, left ventri-
cular hypertrophy, low-grade inﬂammation, energy
intake and physical activity.
The study was approved by the regional ethics
committee of what was formerly known as the Southern
Norway Regional Health Authority. The study is
registered in the ClinicalTrials.gov-registry under the
unique trial number NCT00273104. Written informed
consent was provided by all the participants.
Intervention
Both treatment groups were seen by an internist half
yearly and by a dietician when required. Changes in
medicationsweremade on an individual basis by both the
patients’ general practitioner and by hospital physicians.
Patients in the surgical group completed a low-calorie
diet (3.3–3.8 MJ/day) in 3–6 weeks preceding surgery.
A Roux-en-Y gastric bypass surgery was performed
laparoscopically in 74 of the 76 surgically treated
patients. The gastric pouch was about 25 ml, while
the intestinal limb lengths were measured as follows:
alimentary limb, median 120 (range 80–250) cm;
biliopancreatic limb, median 100 (range 50–170) cm;
and common channel, variable length. The bariatric
Pre-screened (n=228)
Screened (n=181)
Not eligible (n=47)
Completed the
study (n=76)
Not enrolled (n=35)
-BMI<35 kg/m2 (n=3)
-Previous malabsorptive surgery (n=3)
-Pregnancy (n=2)
-Withdrew (n=17)
-Postponed treatment (n=4)
-Alternative bariatric procedures (n=6)
Withdrew (n=2)
Excluded due to
pregnancy (n=2)
Completed the
study (n=63)
Withdrew (n=2)
Excluded due to
cancer (n=1)
Intensive lifestyle
intervention (n=66)
Gastric bypass
surgery (n=80)
Enrolled (n=146)
Figure 1 Flow of participants throughout the study.
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surgeons tended to choose longer limbs in the heaviest
patients. After surgery, a standardised regimen of
dietary supplements (23) and a proton pump inhibitor
were prescribed to all patients. Patients with a high risk
of venous embolism were prescribed low-molecular
weight heparin. During follow-up, patients allocated to
surgery were examined by a bariatric surgeon 6 weeks
post surgery, while groups of patients were seen by a
dietician quarterly. To optimise the result of the
procedure patients were encouraged, both before and
after the surgery, to normalise their eating behaviour
and to increase their physical activity level.
The majority (59/63) of patients in the lifestyle group
were referred to a rehabilitation centre specialising in the
care of morbidly obese patients (Evjeklinikken). Using a
cognitive approach the programmeat this centre aimed to
induce a weight loss of at least 10%. Each patient was
motivated to increase their physical activity and to
normalise their eating habits. The 1-year lifestyle
programme comprises four stays at the rehabilitation
centre lasting for either 1 week or 4 weeks (Fig. 2).
The daily programme was divided between organised
physical activity (3–4 h) and different psychosocially
oriented interventions. The interventions involved indi-
vidual consultations with amedical doctor, a nutritionist,
a physiotherapist and a trained nurse. Those leading the
counselling interviews were trained in motivational
interviewing, a client-centred counselling style that
aims to invoke behaviour change. The patients also took
part in group sessions focusing on emotional aspects of
sedentarybehaviouraswell as classroom lessons on topics
related to nutrition, physical activity and co-morbidities.
No special diet or weight-loss drugs were prescribed,
but patients were encouraged to follow the guidelines of
the Norwegian National Council of Nutrition (24), which
recommend that the daily intake of protein, fat,
carbohydrate and alcohol should account respectively
for 10–20,!30, 50–60 and!5% of energy consumed.
Outside of these stays, patients were contacted by phone
once every2weeks. Theywere encouraged to self-monitor
their eating habits and physical activities, as well as to
visit their general practitioner for a consultation and
weight control check once every 4 weeks. The remaining
four participants were allocated to two rehabilitation
centres with comparable intervention programmes. Fifty-
four patients (86%) attended all scheduled centre visits.
Outcome variables
Demographic and clinical data were recorded on
standardised forms. Height, weight and waist and hip
circumferences were measured with patients in an
upright position wearing light clothing and no shoes.
A 75 g oral glucose tolerance test was performed at
0800 h after an overnight fast. Type 2 diabetes was
diagnosed in patients who used glucose-lowering agents
or had fasting serum glucose R7.0 mmol/l and/or 2 h
serum glucoseR11.1 mmol/l (25). Remission of diabetes
was deﬁned as either partial (serum glucose levels
below the diagnostic cut-off values and HbA1c !6.5%)
or complete (fasting serum glucose !5.6 mmol/l, 2 h
glucose!7.8 mmol/l andHbA1c!6.2%) in the absence
of glucose-lowering agents (26). Combined remission
rates (partial and complete) are presented unless
otherwise speciﬁed.
Blood pressure was measured three times after at
least 5 min rest. The average of the second and third
measurements was registered. Patients using anti-
hypertensive drugs, as well as those with systolic
blood pressure R140 mmHg and/or diastolic blood
pressure R90 mmHg (27) were categorised as having
hypertension. Remission of hypertension was deﬁned
as blood pressure below the diagnostic cut-off values in
the absence of anti-hypertensive drugs.
Metabolic syndrome was deﬁned according to the
modiﬁed ATP III criteria (28). Albuminuria was deﬁned
as present if the albumin to creatinine ratio was
R2.5 mg/mmol in men and R3.5 mg/mmol in
women (29). The product of QRS complex duration
times Cornell voltage combination (RaVLCSV3, with
6 mm added in women) was used with a threshold value
of 2440 mm!ms to identify electrocardiographic left
ventricular hypertrophy (30). Regression of electro-
cardiographic left ventricular hypertrophy estimated
by the Cornell voltage-duration product is known to
predict regression of echocardiographic left ventricular
hypertrophy (31).
Dietary intake and physical activity during the
preceding year were assessed through structured
interviews performed by registered dieticians. Data
were recorded on an optically readable food frequency
questionnaire (Department of Nutrition, University of
Oslo, Norway). Similar questionnaires have been
validated using weighted records (32). Questionnaire
data were scanned using Teleform 10.0 (Cambridge,
UK). Dietary intake was calculated using a data-
base assembled from ofﬁcial food composition tables
(Norwegian Nutrition Council, 1995). Calculations
were computer driven (Kostberegningssystem 6.0;
University of Oslo, Norway). Time spent performing
light (e.g. casual walking), moderate (e.g. brisk
walking) and vigorous (e.g. jogging) intensity aerobic
physical activities in periods of 10 min or more was
recorded. Participants who performed 150 min or
more per week of moderately intense aerobic physical
activities were considered to be physically active, as
1 week
Rehabilitation
center
4 weeks
Rehabilitation
center
1 week
Rehabilitation
center
1 week
Rehabilitation
center
10 weeks
Home
23 weeks
Home
12 weeks
Home Figure 2 Schedule of stays during the
1-year lifestyle programme at Evjeklinikken.
Weight reduction and cardiovascular risk 737EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010) 163
www.eje-online.org
were those participants who performed 60 min or
more per week of vigorously intense aerobic physical
activities (33).
Perioperative (ﬁrst 30 days) and late (after 30 days)
complications were recorded in each patient’s record ﬁle.
In addition, all medical emergencies, hospitalisations
and gastrointestinal side effects were reported on
standardised self-report questionnaires. Reported symp-
tomatic postprandial hypoglycaemia was documented
by blood glucose!2.8 mmol/l (34). Complications and
medical emergencies not recorded in each patient’s
record ﬁle at our hospital were veriﬁed by reports from
other institutions.
Laboratory analyses
Blood samples were collected either in the fasting state
or during the oral glucose tolerance test. Samples
clotted 30 min at room temperature, and serum was
separated by centrifugation. Analyses of blood lipids and
glucose were performed by dry reagent slide technology
on the Vitros 950 Analyzer until November 2006 and
the Vitros FS 5.1 Analyzer (Ortho-Clinical Diagnostics,
New York, NY, USA) thereafter. HbA1c was analysed
using HPLC on Tosoh HLC-723 G7 (Tosoh Corporation,
Tokyo, Japan).
Serum samples collected during the oral glucose
tolerance test were either stored atK80 8C or analysed
on the day of collection (glucose). Insulin, C-reactive
protein and adiponectin were measured in stored serum
obtained before the glucose ingestion. Insulin was
analysed using an RIA (Millipore Corporation, Billerica,
MA, USA), whereas C-reactive protein and adiponectin
were analysed using enzyme immunoassays (R&D
systems, Minneapolis, MN, USA). All samples were
measured in duplicate. The intra- and inter-assay
coefﬁcients of variation were !10% for all assays.
Albumin and creatinine in urine were analysed using
Konelab 60i (Thermo Electron Corporation, Helsinki,
Finland) until August 2008 and Vitros FS 5.1
Chemistry System thereafter.
Statistical analysis
The sample size of the MOBIL study was calculated
(80% statistical power, a-level of 0.05 and equal
distribution to the treatment groups) based on antici-
pated remission rates of type 2 diabetes and obstructive
sleep apnoea. Given remission rates of type 2 diabetes of
70% in the surgery group and 20% in the lifestyle
group, at least 30 subjects with type 2 diabetes were
required. Expecting a prevalence of type 2 diabetes of
25% and a dropout rate of 30% from the screening
examinations, a minimum of 172 subjects were
required for screening.
Data are presented as mean (S.D.) or number (%)
unless otherwise speciﬁed. Skewed data were trans-
formed using natural logarithms to approximate
normality. Between-group comparisons at baseline
were analysed using independent samples t-test or
Mann–Whitney U test for continuous variables and c2
or Fisher’s exact test for categorical variables. Within-
group comparisons were performed using paired
samples t-test or repeated measures ANOVA for
continuous variables and McNemar test for dichoto-
mised variables. Between-group changes in outcome
variables were assessed using logistic and linear
regression analyses, analysis of covariance, repeated
measures ANOVA and Fisher’s exact test. Furthermore,
changes in categorical and continuous variables were
adjusted for baseline differences. In addition, continu-
ous variables were, in the entire study population,
adjusted for gender, age, BMI at baseline and changes in
relevant medication. Regression analyses were used to
identify predictors of remission of diabetes and
hypertension and to explore the independent effects of
several variables on changes in HbA1c and blood
pressure. For each variable, only subjects who had
values available at both baseline and follow-up are
presented and included in the analyses. There were
!5% missing and/or excluded data unless otherwise
noted. The signiﬁcance level was P!0.05. Statistical
analyses were performed using SPSS 16.0 (SPSS Inc.,
Chicago, IL, USA).
Results
Baseline characteristics of participants
Patient ﬂow throughout the study is shown in Fig. 1.
Of the 146 patients included, 80 chose to have surgery
and 66 chose to participate in a lifestyle intervention
programme. The completion rate was 95%. Baseline
characteristics of the participants who completed the
study are shown in Table 1. No signiﬁcant differences
were found between the two study groups in terms
of sex, ethnicity, obesity-related comorbidities or the
usage of weight-loss drugs or statins. However, patients
who chose gastric bypass surgery were on average
4 years younger and 12 kg heavier than those in the
lifestyle group.
Weight reduction
Weight changes in the two treatment groups during the
study are shown in Fig. 3A. Mean (S.D.) percentage
1-year weight reduction was 30% (8) in the surgery
group and 8% (9) in the lifestyle group (within-groups
both P!0.001 and between-groups P!0.001). This
corresponds to a mean (S.D.) loss of excess weight above
25 kg/m2 of 67% (18) and 20% (23) (P!0.001)
respectively.
The cumulative distribution of percentage weight
change in the two treatment groups is shown in Fig. 3B.
Within the lifestyle group, 62% lostR5% of their initial
738 D Hofsø and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010) 163
www.eje-online.org
weight, while 38% lost R10% of their initial weight.
Within the surgery group, all subjects experienced a
weight reduction O10% of their initial weight.
Changes in measures of obesity, glucose
metabolism, blood pressure, lipids and
inﬂammatory markers
With the exception of pulse pressure, changes in
anthropometric measures, blood pressures and bio-
chemical risk factors were signiﬁcantly greater in the
surgery group than in the intensive lifestyle group
(Table 2). Both treatment groups experienced a
signiﬁcant reduction in all measures of obesity, glucose
metabolism, blood pressure, total and low-density
lipoprotein cholesterol, triglycerides and C-reactive
protein during follow-up (all P%0.034). Adiponectin
increased signiﬁcantly in both treatment groups (both
P!0.001), whereas high-density lipoprotein choles-
terol increased signiﬁcantly only in the surgery group
(P!0.001).
Subgroup analyses including subjects with R10%
weight reduction showed that multi-adjusted (gender,
age, BMI, baseline value and change in relevant
medications) between-group changes in HbA1c and
systolic and diastolic blood pressures did not differ
signiﬁcantly between the surgically and the conserva-
tively treated groups (mean (95% CI) 0.0 (K0.2 to 0.2)
%, PZ0.965;K2 (K7 to 4) mmHg, PZ0.536; andK3
(K7 to 1) mmHg, PZ0.115, respectively).
Regression analyses, including percentage weight
change, treatment choice, gender, age, BMI, baseline
value and change in relevant medication as indepen-
dent variables, showed that weight loss, but not
treatment choice, was signiﬁcantly associated with
reduction in HbA1c and systolic blood pressure, but
not diastolic blood pressure (R2Z0.712, bZ0.206,
PZ0.008; R2Z0.580, bZ0.313, PZ0.001; and
R2Z0.423, bZ0.140, PZ0.210).
Table 1 Participant characteristics at baseline. Data are given as
mean (S.D.), median (range), or n (%). Differences between
categorical data were determined using either c2 or Fisher’s exact
test, whilst independent sample t-test or Mann–Whitney U test were
used for continuous data.
Surgery
(nZ76)
Lifestyle
(nZ63) P value
Age (years) 42.8 (10.5) 47.0 (11.0) 0.023
Gender (female) 53 (70%) 44 (70%) 0.989
Caucasian 74 (97%) 61 (97%) 0.849
Type 2 diabetes 20 (26%) 18 (29%) 0.766
Duration of type
2 diabetes (years)
1 (0 to 31) 0 (0 to 16) 0.235
Hypertension 41 (54%) 40 (64%) 0.256
Metabolic syndrome 58 (76%) 44 (70%) 0.390
Albuminuria 11 (15%)a 7 (13%)b 0.745
Left ventricular hypertrophy 13 (17%)c 7 (11%)d 0.319
Coronary heart disease 5 (7%) 4 (7%) 1.000
Weight (kg) 137 (21) 125 (20) 0.001
Body mass index (kg/m2) 46.7 (5.7) 43.3 (5.0) !0.001
Waist circumference (cm) 135 (13) 129 (12) 0.009
Waist-to-hip ratio 0.99 (0.09) 0.97 (0.09) 0.447
Glucose, fasting (mmol/l) 6.8 (2.3) 6.4 (1.7) 0.520
Glucose, 2 h (mmol/l) 7.5 (3.4)e 7.6 (3.1)f 0.877
Insulin, fasting (pmol/l) 247 (106) 228 (111) 0.254
HbA1c (%) 5.9 (1.1) 5.7 (0.8) 0.520
Systolic BP (mmHg) 133 (18) 135 (16) 0.510
Diastolic BP (mmHg) 83 (11) 83 (10) 0.857
Pulse pressure (mmHg) 51 (13) 52 (14) 0.476
Total cholesterol (mmol/l) 5.1 (1.1) 5.2 (1.0) 0.724
LDL cholesterol (mmol/l) 3.1 (0.9) 3.3 (0.9) 0.226
HDL cholesterol (mmol/l) 1.2 (0.3) 1.2 (0.3) 0.457
Triglycerides (mmol/l) 1.8 (1.0) 1.5 (0.9) 0.013
C-reactive protein (mg/l) 2.9 (2.4) 3.2 (3.9) 0.408
Adiponectin (mg/ml) 5.7 (3.2) 5.8 (3.4) 0.721
Energy intake (MJ/day) 11.2 (4.5)g 12.0 (3.8)h 0.293
Physically activei 7 (10%)g 10 (18%)h 0.179
Currently smoking 21 (28%) 21 (33%) 0.466
Weight loss drugs 4 (5%) 2 (3%) 0.689
Statins 10 (13%) 7 (11%) 0.798
LDL, low density lipoprotein, HDL, high density lipoprotein.
anZ72; bnZ53; cnZ75; dnZ62; enZ64; fnZ55; gnZ73; hnZ55;
iR150 min of moderately intense or R60 min of vigorously intense aerobic
physical activity per week.
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All participants had 2 h glucose O2.8 mmol/l at
baseline. In contrast, 2 (4%) patients in the lifestyle
group and 15 (23%) patients in the surgery group had
2 h glucose !2.8 mmol/l after the intervention
(PZ0.003).
Type 2 diabetes and hypertension
Among participants with type 2 diabetes, HbA1c was
reduced from 6.6% (1.0) to 6.3% (0.9) in the lifestyle
group and from 7.1% (1.5) to 5.8% (0.5) in the surgery
group (adjusted between-group difference, PZ0.003).
Moreover, the hypertensive subgroups’ systolic blood
pressure declined from 144 mmHg (16) to 125 mmHg
(12) after the surgical procedure and from 143 mmHg
(15) to 130 mmHg (14) after the lifestyle intervention
(adjusted between-group differences, PZ0.061).
Furthermore, the number of diabetic subjects using
glucose-lowering agents dropped (from 11 to 6) in the
surgery group and increased (from 6 to 10) in the
lifestyle group (between-group difference, PZ0.017). In
contrast, the reduction in the number of hypertensive
participants using anti-hypertensive drugs did not differ
signiﬁcantly between the surgery group (from 24 to 21)
and the lifestyle group (from 30 to 25) (between-group
difference, PZ1.00).
The remission rates of type 2 diabetes and hyperten-
sion related to weight change after gastric bypass
surgery and lifestyle intervention are shown in Fig. 4.
The remission rates of both conditions were signiﬁcantly
higher after surgical treatment than after lifestyle
intervention. Complete remission of type 2 diabetes
was signiﬁcantly more frequent in the surgery group
than in the lifestyle group (11/14 vs 0/6, PZ0.002).
Multiple regression analyses demonstrated that no
usage of glucose-lowering agents and anti-hypertensive
drugs at baseline were, independent of percentage
weight change and treatment choice, associated with
remission of type 2 diabetes (PZ0.023) and hyperten-
sion (P!0.001). In addition, univariate linear
regression analyses showed that greater reductions in
HbA1c and systolic blood pressure were associated
with surgical treatment (bZK0.408, PZ0.011 and
bZK0.187, PZ0.096 respectively). Inclusion of
percentage weight change in the regression analyses
showed that weight loss mediated the effects of treat-
ment choice on these outcomes (bZ0.406, PZ0.160
and bZ0.142, PZ0.410 respectively). Furthermore,
weight loss was signiﬁcantly associated with reductions
in HbA1c and systolic blood pressure (bZ0.926,
PZ0.002 and bZ0.423, PZ0.016 respectively).
Metabolic syndrome, albuminuria and left
ventricular hypertrophy
The changes in the number of individuals with
metabolic syndrome (K44 vs K14), albuminuria
(K7 vs 3) and left ventricular hypertrophy (K10 vs
K2) were signiﬁcantly greater in the surgery group
than in the lifestyle group (Fig. 5). The prevalence
of metabolic syndrome reduced signiﬁcantly in
both treatment groups (both P%0.001), while the
Table 2 Changes from baseline in various continuous variables. Unadjusted within-group changes are given as mean (S.D.). Adjusted
between-group differences and corresponding P value were calculated with the use of analysis of covariance and presented as mean (95%
CI). All between-group differences were adjusted for gender, age, baseline body mass index, and baseline values. Furthermore, fasting and
2-h glucose, insulin and HbA1c were adjusted for change in the usage of glucose lowering agents; systolic and diastolic blood pressure and
pulse pressure were adjusted for change in the usage of anti-hypertensive drugs; and total cholesterol, low and high density lipoprotein
cholesterol, and triglycerides were adjusted for the change in the usage of statins.
Surgery (nZ76) Lifestyle (nZ63)
Adjusted between-group
difference, mean (95% CI) P value
Weight (kg)a K41.3 (13.1) K10.7 (12.0) K27.6 (K31.7 toK23.5) !0.001
Body mass index (kg/m2) K14.0 (4.1) K3.7 (4.2) K9.4 (K10.8 toK8.0) !0.001
Waist circumference (cm)a K30.3 (10.5) K10.3 (10.6) K17.8 (K21.3 toK14.4) !0.001
Waist-to-hip ratio K0.06 (0.06) K0.01 (0.07) K0.05 (K0.07 toK0.03) !0.001
Glucose, fasting (mmol/l) K1.9 (2.0) K0.8 (1.0) K0.8 (K1.1 toK0.5) !0.001
Glucose, 2 h (mmol/l) K4.2 (3.2) K1.6 (1.9) K2.4 (K3.0 toK1.8) !0.001
Insulin, fasting (pmol/l) K142 (96) K53 (84) K77 (K100 toK54) !0.001
HbA1c (%) K0.4 (0.9) K0.1 (0.5) K0.2 (K0.3 toK0.0) 0.047
Systolic blood pressure (mmHg) K14 (16) K10 (15) K4 (K8 toK0) 0.028
Diastolic blood pressure (mmHg) K12 (10) K6 (11) K5 (K8 toK2) 0.002
Pulse pressure (mmHg) K2 (14) K4 (12) 1 (K3 to 4) 0.760
Total cholesterol (mmol/l) K1.2 (1.1) K0.7 (0.8) K0.4 (K0.6 toK0.2) !0.001
LDL cholesterol (mmol/l) K1.0 (0.8) K0.5 (0.7) K0.5 (K0.7 toK0.4) !0.001
HDL cholesterol (mmol/l) 0.2 (0.3) 0.0 (0.2) 0.2 (0.2 to 0.3) !0.001
Triglycerides (mmol/l) K0.9 (1.0) K0.4 (0.8) K0.2 (K0.3 toK0.0) 0.014
C-reactive protein (mg/l) K2.1 (2.2) K1.4 (3.6) K1.0 (K1.5 toK0.6) !0.001
Adiponectin (mg/ml) 3.9 (3.8) 1.8 (3.2) 2.0 (1.0 to 3.0) !0.001
Energy intake (MJ/day) K4.7 (4.5) K3.5 (3.5) K1.7 (K2.3 toK1.0) !0.001
LDL, low density lipoprotein, HDL, high density lipoprotein.
aNot adjusted for body mass index.
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prevalence of left ventricular hypertrophy was signi-
ﬁcantly reduced in only the surgery group (PZ0.002).
In contrast, the prevalence of albuminuria did not
change signiﬁcantly within either treatment group.
Lifestyle and medications
Although both treatment groups reported signiﬁcantly
lower energy intake at 1 year than at baseline (both
P!0.001), the reduction was signiﬁcantly greater in
the surgery group than in the lifestyle group (Table 2).
The number of subjects in the surgery group and
lifestyle group which either moved from being inactive
to active (12 vs 18), stayed inactive or active (57 vs 32)
or moved from being active to inactive (4 vs 5) differed
signiﬁcantly between the groups (Fig. 6). Overall, there
was a greater increase in the physical activity level of
the lifestyle group than the surgery group. However, the
median (range) time spent performing physical activi-
ties with moderate or vigorous intensity after the
interventions did not differ signiﬁcantly between the
surgery and lifestyle groups, 20 (0–510 min) versus 65
(0–660 min), PZ0.148.
Usage of weight-loss medications was stopped in all
surgically treated patients and started in only one
patient in the lifestyle group. The change in the number
of individuals using statins did not differ signiﬁcantly
between the surgery and the lifestyle (10 vs 3,
PZ0.114).
Last observation carried forward
In additional calculations, missing values were replaced
by the last observed value of the respective variable
(data not shown). These results did not alter the
conclusions of the study.
Adverse events
Median (range) post-operative stay was 2 (1–9) days.
Perioperative complications in the surgery group
included one gastrojejunal anastomotic leakage,
which was successfully re-operated on during the ﬁrst
post-operative day, one major bleeding at the site of the
trocar insertion, which needed a blood transfusion, and
two pneumonias treated effectively with antibiotics.
Late complications in the surgery group included four
patients with symptomatic cholelithiasis (imaging
veriﬁed), two patients with marginal ulcers, ﬁve patients
with postprandial hypoglycaemia, one patient with a
fracture of the ﬁfth right proximal phalange and one
patient with myocardial infarction. In the lifestyle
group, one patient was diagnosed with breast cancer,
one patient suffered a right ankle fracture that was
treated with a stabilising cast and complicated by a deep
venous thrombosis and one patient developed chole-
lithiasis. There were no deaths.
In total, 48% (33/69) of patients in the surgery group
and 7% (4/59) of patients in the lifestyle group
developed gastrointestinal symptoms, including
abdominal pain, nausea, vomiting, diarrhoea and
constipation (P!0.001).
Discussion
To our knowledge, this is the ﬁrst controlled, clinical trial
that has sought to evaluate the effects of gastric bypass
surgery and intensive lifestyle intervention on cardio-
vascular risk factors. When compared with the lifestyle
group, the surgery group had higher remission rates
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Figure 5 The prevalence of metabolic syndrome, albuminuria and
left ventricular hypertrophy in the treatment groups at both baseline
and 1-year follow-up. Between-group differences at 1 year were
adjusted for differences in prevalence at baseline using logistic
regression analyses. P values are for comparisons between surgery
and lifestyle groups.
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Figure 4 Remission of type 2 diabetes and hypertension at
1 year correlated to percentage weight change in individuals
treated with gastric bypass surgery or intensive lifestyle
intervention. Red triangles represent patients treated with gastric
bypass surgery, while blue circles represent subjects who chose
lifestyle intervention. Open triangles/circles denote complete
remission of type 2 diabetes and remission of hypertension, half
ﬁlled triangles/circles denote partial remission of type 2 diabetes
and ﬁlled triangles/circles denote no remission. For deﬁnitions of
partial and complete remission of type 2 diabetes, see ‘Subjects
and methods’ section. Mean percentage weight changes
(black diamonds) within the groups are shown with bars
extending from the diamonds representing 95% CI. Odds
ratios (OR) were calculated using logistic regression analyses.
Combined (partial and complete) remission of type 2 diabetes
was used in the analysis.
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of type 2 diabetes and hypertension, as well as greater
reductions in the prevalence of metabolic syndrome,
albuminuria and left ventricular hypertrophy. Notably,
intensive lifestyle intervention was also associated with
favourable changes in measures of glucose metabolism,
blood pressure, lipids and low-grade inﬂammation.
Strengths and weaknesses of the study
The strengths of this study include the prospective
design, the fact that the control group obtained a
signiﬁcant weight loss from lifestyle intervention and
the high participant completion rate. Limitations of the
study include the lack of randomisation (addressed in
‘Subjects and methods’ section), a larger intervention
delay in the surgery group and the short-term follow-
up. Furthermore, the diagnoses of type 2 diabetes and
hypertension were, in the absence of hypoglycaemic or
anti-hypertensive drugs, based on only one measure-
ment and not repeated measurements as recommended
(25, 27). Finally, the majority of the study population
was of Europoid origin, meaning that the results of
this study cannot be generalised to include other
ethnic groups.
Type 2 diabetes and hypertension
Both the case controlled Swedish Obese Subjects (SOS)
study (10) and the Australian randomised controlled
clinical trial (11) demonstrated that 2 year remission
rates of type 2 diabetes were signiﬁcantly higher in
patients treated with bariatric surgery than in con-
servatively treated controls. The SOS study also reported
higher remission rates of hypertension in the surgery
group. Our study extends these ﬁndings by showing that
morbidly obese patients treated with gastric bypass
surgery were more likely to achieve remission of type 2
diabetes and hypertension than those who participated
in a comprehensive lifestyle intervention programme.
In addition to a shorter intervention period, our study
differs from these previous trials in several ways. First, in
contrast with our standardised and comprehensive
lifestyle programme, the above two studies are notable
for the fact that non-surgical treatment varied consider-
ably and that weight loss was negligible. Second, our
surgical procedure was gastric bypass, whereas purely
restrictive, bariatric procedures were mainly imple-
mented in the two other studies. Accordingly, the
average 1-year weight reduction was more pronounced
in our surgical group. Third, our deﬁnition of remission
of type 2 diabetes differed slightly from the previous
studies. Finally, the Australian study differed in the
sense that it only included those patients who had type
2 diabetes of !2 years duration and a BMI of between
30 and 40 kg/m2. Nevertheless, despite these
differences, the remission rate of diabetes in our surgical
group was nearly identical with rates in these previous
studies (70 vs 71 and 72%). Furthermore, while
hypertension was resolved in approximately half the
surgical patients in our study, it did so in only one-third
of the patients in the SOS study.
Our study shows that weight reduction, and not
treatment choice, predicted improvement in glycaemic
control and systolic blood pressure. Furthermore, most
of the beneﬁcial metabolic effects were observed after a
weight reduction of R10%. Accordingly, the metabolic
effect of gastric bypass surgery seems to be mediated
through weight reduction.
Despite extensive weight loss, type 2 diabetes and
hypertension in a substantial number of surgically
treated patients were not resolved. In contrast, remis-
sion of these conditions was observed in some lifestyle
group patients despite only modest weight reduction.
These ﬁndings might be explained by differences in the
severity of the conditions and the possible beneﬁcial
effect of increased physical activity. Indeed, the absence
of glucose-lowering drugs and anti-hypertensive
medication independently predicted remission of both
diabetes and hypertension. Furthermore, compared
with subjects treated with surgery, a signiﬁcantly higher
proportion of the participants in the lifestyle group
became physically active.
Both blood glucose and blood pressure are continuous
risk factors for death and cardiovascular disease (35, 36).
The observed decline in these measures in both
intervention groups may therefore have positive health
effects. Conversely, the ﬁve cases of symptomatic
postprandial hypoglycaemia and the large proportion
(23%) of patients with 2 h glucose !2.8 mmol/l in
the gastric bypass group raise some concerns. Severe
postprandial hypoglycaemia after Roux-en-Y gastric
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Figure 6 Change in physical activity during 1-year follow-up. The
proportion of participants who went from being physically active
(R150 min of moderate orR60 min of vigorous aerobic physical
activity per week) to inactive (reduced) were still physically active or
inactive (unchanged) or went from being physically inactive to active
(increased). The changes were adjusted for baseline activity level
using linear regression analysis. P value is for comparisons
between surgery and lifestyle groups.
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bypass surgery has been reported previously and
post-surgical nesidioblastosis may contribute to this
complication (37). Furthermore, severe and sympto-
matic hypoglycaemia in type 2 diabetic subjects has been
shown to be associated with increased mortality (38).
Consequently, it cannot be excluded that the reduction in
2 h glucose observed after Roux-en-Y gastric bypass
surgery may also have negative long-term health effects.
Other cardiovascular risk factors
Surgical therapy was superior to lifestyle intervention
both in terms of the resolution of metabolic syndrome,
left ventricular hypertrophy and microalbuminuria, as
well as with respect to improvements in inﬂammatory
markers. In line with previous studies, we report that
weight reduction was associated with resolution of
metabolic syndrome (11, 17), beneﬁcial changes in
C-reactive protein and adiponectin levels (16) and
reduction in left ventricular mass (12). Improvement
in all renal parameters, including albuminuria, has
been reported after gastric bypass surgery (13).
Similarly, weight reduction after lifestyle intervention
has been reported to resolve albuminuria (17). In
contrast to this ﬁnding and closer to our own results,
modest weight reduction in the intensive lifestyle group
of the Diabetes Prevention Program did not reduce
albumin excretion signiﬁcantly (39).
Clinical and research implications of the work
In sum, we have shown that gastric bypass surgery is
more effective than intensive lifestyle intervention in
terms of improving type 2 diabetes and obesity-related
cardiovascular risk factors. However, morbidly obese
patients treated with lifestyle intervention also experi-
enced signiﬁcant and meaningful improvements in most
cardiovascular risk factors, and signiﬁcantly more
patients in the lifestyle group than the surgery group
became physically active. Gastric bypass surgery was
associated with a signiﬁcantly higher risk of gastro-
intestinal symptoms and complications as reported
previously (40). Furthermore, although a speciﬁed set
of dietary supplements seems to prevent vitamin
deﬁciencies after gastric bypass surgery (23), several
deﬁciencies may occur if an inadequate supple-
mentation is prescribed (41). Finally, even though
reduced overall mortality after bariatric surgery has
been reported (42), it is still unclear whether short-term
improvement in obesity-related cardiovascular risk
factors translates into long-term reduced cardiovascular
morbidity and mortality. Our results indicate that when
treating morbidly obese patients, gastric bypass surgery
should not, despite its ability to improve risk factors,
be considered the default course of treatment. Rather,
both patient and physician should consider the possible
side effects of this treatment, and, where appropriate,
take up alternative conservative treatments. Indeed,
intensive behavioural intervention has been shown to
result in long-term weight reduction in some patients
(43), while improved physical ﬁtness is known to reduce
all cause mortality (44). Moreover, it should be
emphasised that if the success of bariatric surgery is to
be optimised then behavioural changes are also
necessary (45). Future studies comparing surgery and
non-surgical treatment programmes should address the
effect of these treatments on long-term cardiovascular
morbidity and mortality.
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Abstract 
Objective: The effects of various weight loss strategies on pancreatic beta cell function remain 
unclear. We aimed to compare the effect of intensive lifestyle intervention (ILI) and Roux-en-
Y gastric bypass surgery (RYGB) on beta cell function.  
Design: One year controlled clinical trial (ClinicalTrials.gov identifier NCT00273104). 
Methods: 119 morbidly obese participants without known diabetes from the MOBIL study 
[mean (SD) age 43.6 (10.8) years, BMI 45.5 (5.6) kg/m2, 84 women] were allocated to RYGB 
(n=64) or ILI (n=55). The patients underwent repeated oral glucose tolerance tests (OGTTs) 
and were categorised as having either normal (NGT) or abnormal glucose tolerance (AGT). 
Twenty nine normal weight subjects with NGT [age 42.6 (8.7) years, BMI 22.6 (1.5) kg/m2, 
19 women] served as controls. OGTT-based indices of beta cell function were calculated.  
Results: One year weight reduction was 30 (8) % after RYGB and 9 (10) % after ILI, (P < 
0.001). Disposition index (DI) increased in all treatment groups (all P < 0.05), although more 
in the surgery groups (both P < 0.001). Stimulated proinsulin-to-insulin (PI/I) ratio decreased 
in both surgery groups (both P < 0.001), but to a greater extent in the surgery group with AGT 
at baseline (P < 0.001). Post surgery, patients with NGT at baseline had higher DI and lower 
stimulated PI/I ratio than controls (both P < 0.027). 
Conclusions: Gastric bypass surgery improved beta cell function to a significantly greater 
extent than intensive lifestyle intervention. Supra-physiological insulin secretion and 
proinsulin processing may indicate excessive beta cell function after gastric bypass surgery.   
  
 

Introduction  
Obesity is a major risk factor for type 2 diabetes, with approximately one out of three 
morbidly obese subjects (BMI  40 kg/m2 or BMI  35 kg/m2 with at least one obesity related 
comorbidity) having  type 2 diabetes (1). Reduced insulin sensitivity and beta cell dysfunction 
represent the core pathophysiologic defects in type 2 diabetes (2). It is well-known that weight 
reduction enhances insulin sensitivity in obese subjects (3), with this contributing to the 
improvement in glycaemic control reported after lifestyle intervention (4) and bariatric 
surgery (5). By contrast, the association between weight reduction and restoration of beta cell 
function is less clear. Modest weight loss induced by diet alone (6) or in combination with 
exercise (7) in older non-diabetic overweight and obese subjects has been shown to enhance 
beta cell function. Moreover, results from the Diabetes Prevention Program which 
predominantly included obese, middle-aged subjects with impaired glucose tolerance (IGT), 
indicate improved insulin secretion relative to insulin sensitivity after one year of intensive 
lifestyle intervention (8). By contrast, 24 months of diet and endurance exercise did not 
improve beta cell function in Japanese Americans with impaired glucose tolerance (9). 
Furthermore, recovery of beta cell function has been reported after bariatric surgery (10-12). 
Increased insulin secretion post surgery could contribute to high remission rates of type 2 
diabetes after bariatric surgery (5) as well as to postprandial hypoglycaemia, a phenomenon 
which has drawn much attention recently (13, 14).  
 Given this background, we aimed to compare in morbidly obese patients without 
known diabetes the one year effect of intensive lifestyle intervention (diet and physical 
activity) and Roux-en-Y gastric bypass on beta cell function as assessed by oral glucose 
tolerance test (OGTT) derived indices.  
 
 

Methods 
Participants and study design  
This is an ancillary study to the MOBIL study (Morbid Obesity treatment, Bariatric surgery 
versus Intensive Lifestyle intervention study, ClinicalTrials.gov identifier: NCT00273104) 
(15).  It includes a subset of 119 morbidly obese participants without known diabetes who 
underwent an OGTT before and after intervention. In addition, 29 normal weight (BMI < 25 
kg/m2) subjects with normal glucose tolerance (NGT) served as a control group (data from 27 
of these subjects has been published previously (16)).  
 The MOBIL study aimed to address changes in several health outcomes related to 
obesity, with details concerning the design and intervention published previously (15).  In 
short, this one year controlled clinical trial included 146 consecutively recruited morbidly 
obese subjects predominantly of European descent and was conducted at a public tertiary care 
centre in Norway between December 2005 and June 2009. Patients in the surgery group were 
allocated to laparoscopic Roux-en-Y gastric bypass, whereas patients who chose lifestyle 
intervention were referred to a rehabilitation centre specialising in the care of morbidly obese 
patients (Evjeklinikken A/S).  The one year lifestyle programme aimed to induce a weight loss 
of at least 10% and comprised of four stays at the centre lasting for either one week or four 
weeks (total 7 week stay). The daily programme was divided between organised physical 
activity (3-4 hours) and different psychosocially oriented interventions. No special diet or 
weight loss drugs were prescribed, but patients were encouraged to follow the guidelines of 
the Norwegian National Council of Nutrition. Outside of these stays patients were contacted 
by phone once every two weeks. The patients were encouraged to self-monitor their eating 
habits and physical activity, as well as to visit their general practitioner regularly.  
The regional ethics committee of the Southern Norway Regional Health Authority 
approved the study. Written informed consent was provided by all participants. 
 

 
Oral glucose tolerance test  
A 75 g OGTT was performed at 8:00 am after an overnight fast, with venous blood samples 
obtained at 0, 30, and 120 minutes for determination of serum glucose, insulin, c-peptide, and 
proinsulin. Treatment with hypoglycaemic agents was terminated two weeks prior to the 
OGTT for patients receiving such treatment. On the day of the OGTT no medications were 
taken prior to the test.   
 Glucose tolerance status was determined according to the criteria of the World Health 
Organization (17). NGT was defined as fasting glucose < 6.1 mmol/l and 2-h glucose < 7.8 
mmol/l. The abnormal glucose tolerance (AGT, fasting glucose  6.1 mmol/l and/or 2-h 
glucose  7.8 mmol/l) groups included subjects with impaired fasting glucose (IFG), IGT, and 
new onset diabetes mellitus (NODM). Post challenge hypoglycemia was defined as 2-h 
glucose < 2.8 mmol/l. 
  
Calculations  
Several estimates of insulin secretion and insulin sensitivity were initially assessed using 
indices including the available glucose and insulin measurements from the OGTT (18-20). 
However, the insulin sensitivity indices of Belfiore (19) and Stumvoll (20), comprising of  
glucose and insulin concentrations at 120 minutes, seemed to overestimate post surgery 
insulin sensitivity (significantly higher median values than NGT controls, both P  0.001) and 
were therefore not included in the analyses. Consequently, the computer based homeostasis 
model assessment of insulin sensitivity (HOMA-S) was preferred as the insulin sensitivity 
index (18).  
 Insulin secretion was estimated using the insulinogenic index (Ins30/Gluc30,), the 
ratio of the total area under the insulin curve to the total area under the glucose curve (total 
 

AUCIns/Gluc), and the Stumvoll first phase index (fist phaseest: 1283 + 1.829 x Ins30 -138.7 x 
Gluc30 + 3.772 x Ins0) (20). Because insulin secretion is determined in part by the prevailing 
insulin sensitivity, the disposition index (DI), which is the product of insulin sensitivity and 
insulin secretion, yields a better measure of beta cell function (21). Based on the above 
mentioned indices of insulin secretion, three alternative DI`s were calculated.  
 Circulating proinsulin-to-insulin (PI/I) ratio, especially stimulated PI/I ratio (22), has 
previously been used as an estimate of the beta cell`s ability to transform proinsulin to insulin. 
Indeed, elevated PI/I ratio has been associated with IGT (22) and reduced insulin secretion 
(23). PI/I ratios in a fasting and stimulated state (30 minutes after glucose ingestion) were 
therefore calculated.  
 
Laboratory analyses  
HbA1c was analysed using high performance liquid chromatography on Tosoh HLC-723 G7 
(Tosoh Corporation, Tokyo, Japan). Serum samples from the OGTT were separated after 30 
minutes and either stored at -80oC or analysed the same day (glucose). Analyses of glucose 
were performed using dry reagent slide technology on the Vitros 950 Analyser until 
November 2006 and the Vitros FS 5.1 Analyser (Ortho-Clinical Diagnostics, New York, NY) 
thereafter. Serum levels of insulin, c-peptide, and proinsulin (Millipore Corporatio, Billerica, 
MA, USA) were measured by radio immunoassay. All samples were measured in duplicate, 
with serial samples from a given individual run at the same time. Intra- and inter-assay CVs 
were less than 10 % for all assays.  
  
Statistical analysis  
Data are presented as mean (SD) or number (%) unless otherwise specified. Skewed data were 
either transformed using natural logarithms to approximate normality or analysed using non-
 	

parametric tests. Between group comparisons were analysed using one-way analysis of 
variance (ANOVA) with post hoc comparisons (least significant difference, LSD), Mann-
Whitney U test, 2, two-way ANOVA and analysis of covariance (ANCOVA) including 
gender, age and BMI at baseline and baseline value as covariates. Within group comparisons 
between baseline and follow-up variables were compared using paired samples t-test. 
Correlations were calculated with Pearson’s correlation coefficients. Linear regression 
analyses were used to 1) explore a potential hyperbolic relationship between HOMA-S and 
measures of insulin secretion (95% CI of the specialised regression coefficient () in the 
equation ln (insulin secretion) = constant +  x ln (insulin sensitivity) must include -1 and 
exclude 0), and 2) identify possible predictors of change in DI and PI/I ratios (age, gender, 
change in smoking status (stopped/ unchanged/started), family history of type 2 diabetes 
(yes/no), glucose tolerance status (NGT/AGT),  change in physical activity (became 
inactive/unchanged/became active) and treatment choice (surgery/lifestyle), and percent 
weight reduction). The significance level was P < 0.05. Statistical analyses were performed 
using SPSS 16.0 (SPSS Inc., Chicago, IL). 
 
 


Results 
Baseline characteristics of participants  
The 64 patients assigned to gastric bypass were on average 5 years younger and 13 kg heavier 
than the 55 patients in the lifestyle groups (both P < 0.005). Otherwise, within the normal and 
abnormal glucose tolerance groups, the surgery and lifestyle groups were comparable with 
respect to gender and measures of glucose homeostasis (Table 1). In both the surgery and 
lifestyle groups, patients with AGT had higher HbA1c, were less insulin sensitive and had 
lower insulin secretion than patients with NGT (Table 1). In the AGT surgery group 9 
subjects had IFG, 12 had IGT and 11 had NODM, whilst in the AGT lifestyle group 1 had 
IFG, 10 had IGT and 11 had NODM.  
 
Changes in weight, energy intake, medication and glucose tolerance  
Mean (SD) weight reduction in the merged surgery and lifestyle groups was 30 (8) % and 9 
(10) % respectively (P < 0.001). Self reported energy intake was significantly lower after 
surgical treatment than after lifestyle intervention (NGT and AGT groups combined: from 
11.8 (5.1) to 6.9 (1.8) MJ/day and from 12.0 (3.6) to 8.6 (1.9) MJ/day, respectively, P < 
0.001). At baseline, none of the participants used hypoglycaemic agents, whereas three 
patients who chose surgery and two patients who chose lifestyle intervention were taking 
weight loss medications. After surgery, neither hypoglycaemic nor weight loss medications 
were used. By contrast, after one year of lifestyle intervention five patients used 
hypoglycaemic agents (metformin) and three patients were taking weight loss medication. 
AGT was resolved in all gastric bypass surgery patients and in 41 % (9 out of 22) of lifestyle 
intervention patients (P < 0.001).  
 
Glucose, insulin and c-peptide during the oral glucose tolerance test  
 

With the exception of no change in glucose and an increase in insulin and c-peptide at 30 
minutes after surgical treatment, both interventions resulted in a reduction in glucose, insulin, 
and c-peptide at all time points in both glucose tolerance groups (Figure 1). At one year, 
glucose, insulin and c-peptide in the surgery groups were lower at 0 and 120 minutes and 
higher at 30 minutes than in the lifestyle groups. Post challenge hypoglycaemia (< 2.8 
mmol/l) was significantly more prevalent after surgical treatment than after lifestyle 
intervention (NGT and AGT groups combined: 23 % versus 4 %, P = 0.002), but did not 
differ significantly between the NGT and AGT groups (P = 0.768). 
 
Insulin sensitivity and insulin secretion  
HOMA-S increased after both interventions, though to a greater extent in the NGT and AGT 
surgery groups than in the corresponding lifestyle groups (Table 1). The changes in the three 
indices estimating insulin secretion during the OGTT yielded diverging results. While total 
AUCIns/Gluc and fist phaseest decreased or tended to decrease after both interventions in both 
glucose tolerance groups, the opposite was the case for Ins30/Gluc30 (Table 1).  
 
Disposition index  
Pairing HOMA-S with the indices of insulin secretion in subjects with NGT at baseline (n = 
96) showed that the combination of HOMA-S and first phaseest was closest to forming a 
hyperbola: HOMA-S and first phaseest ( = -0.869, 95 % CI (-0.971 to -0.766), n = 94); 
HOMA-S and total AUCIns/gluc ( = -0.796, 95 % CI (-0.922 to -0.671, n = 94); and HOMA-S 
and Ins30/Gluc30 ( = -0.515 95% CI (-0.697 to -0.334), n = 90). This combination was 
therefore used when calculating the DI presented. 
 Figure 2A and 2B depict the one year changes in first phaseest and HOMA-S according 
to glucose tolerance status at baseline in the surgically and conservatively treated groups. The 
 

first phaseest in relation to HOMA-S shifted to the right after treatment in both the surgery and 
lifestyle groups. These findings are consistent with increased insulin secretion relative to 
insulin sensitivity after both interventions as verified by increased DI in subjects with NGT 
and AGT in the surgery and lifestyle groups (Figure 2C). However, the DI increased 
significantly more after surgical treatment than after lifestyle intervention in both glucose 
tolerance groups (Figure 2C). Notably, at one year the DI in the NGT surgery group was even 
higher than in NGT controls (P < 0.001).  
 Exchanging first phaseest with total AUCIns/Gluc when calculating the alternative DI 
yielded similar results to those described above (data not shown).  
 
Proinsulin-to-insulin ratios  
The reduction in stimulated PI/I ratio was greatest after surgical treatment and was most 
pronounced among those with AGT (Figure 3A). Fasting PI/I ratio was significantly reduced 
only in surgically treated patients with AGT (Figure 3B). By contrast, stimulated and fasting 
PI/I ratios did neither change significantly in the NGT group nor the AGT group after lifestyle 
intervention. At one year, stimulated PI/I ratio in the NGT surgery group was even lower than 
in the NGT control group (P = 0.027). 
 
Predictors of improved beta cell function  
In the whole study population, percentage weight change was correlated with both change in 
DI (r = -0.56, P < 0.001) and change in stimulated PI/I ratio (r = 0.29, P = 0.001). 
Furthermore, there was a significant correlation between change in DI and change in 
stimulated PI/I ratio (r = -0.31, P = 0.001). The changes in fasting and stimulated PI/I ratios 
were moderately correlated (r = 0.41, P < 0.001), whereas changes in fasting PI/I ratio 
correlated with neither weight nor DI changes. 
 

 The multiple linear regression analyses showed that 1) treatment choice remained 
associated with change in DI ( = 0.337, P = 0.008) and stimulated PI/I ratio ( = -0.339, P = 
0.022); 2) glucose tolerance status at baseline remained  associated with change in stimulated 
PI/I ratio ( = -0.297, P = 0.002); and 3) weight change remained associated with change in 
DI ( = -0.329, P = 0.008) but not with change in stimulated PI/I ratio ( = -0.027, P = 0.849). 
 
 

Discussion 
The aim of the present study was to compare the effects of Roux-en-Y gastric bypass and 
intensive lifestyle intervention on beta cell function in morbidly obese patients. Our results 
demonstrate that insulin sensitivity adjusted insulin secretion was significantly greater after 
gastric bypass than after lifestyle intervention. In addition, significant reductions in PI/I ratios 
in the surgery groups were observed.  
 
Strengths and weaknesses of the study  
The main strength of the study is the controlled design. The limitations are the use of OGTT-
derived indices not validated in gastric bypass operated patients, the use of indices for the 
calculation of DI which did not fully satisfy the criteria for a hyperbolic relationship, the lack 
of gut hormone analyses, the non-randomised design and the inclusion of predominantly 
white subjects. 
 
Comparison with other studies  
In line with the Diabetes Prevention Program (8) and two smaller weight loss studies (6, 7) we 
confirm that lifestyle intervention is associated with improved insulin sensitivity adjusted 
insulin secretion. A positive effect of weight reduction on beta cell function has also been 
shown in a longitudinal study in Pima Indians (24). Contrasting previous results and the 
results of the present study, DI did not increase after 24 months of lifestyle intervention in a 
study of Japanese Americans with IGT (9). Since the improvement in insulin secretion may be 
proportional to the amount of weight loss (24), these differences may partly be explained by a 
modest weight reduction (2.6 %) in the latter study (9). This notion is further supported by our 
own results, which demonstrate that improvement in DI is partly explained by weight 
reduction. Furthermore, increased DI after gastric bypass is in line with some previous studies 
 

addressing insulin secretion after bariatic surgery in subjects with various degrees of glucose 
tolerance (11, 12). However, in contrast with our findings, Morínigo et al. (10) failed to 
demonstrate an increase in insulin secretory capacity to intravenous glucose in subjects with 
NGT or IGT one year after gastric bypass when accounting for prevailing insulin sensitivity. 
This discrepancy might have several explanations. First, we included a higher number of 
patients than Morínigo et al., and, second, our use of an OGTT derived DI may have yielded a 
greater increase in the DI (11).   
 The pattern of change in the DI calculated by total AUCIns/Gluc and HOMA-S 
resembled that of the DI based on first phaseest and HOMA-S in all groups. This may indicate 
that both early and late phase insulin section increased after both treatments.
 
 
 A decrease in both fasting and stimulated PI/I ratios in the AGT surgery group further 
supports improved beta cell function after gastric bypass. The results are also partly in line 
with some (12, 25), but not all (26), previous studies reporting reduced fasting PI/I ratio after 
bariatric surgery in morbidly obese subjects with normal and abnormal glucose tolerance. To 
the best of our knowledge, the possible effect of gastric bypass on stimulated PI/I ratio has not 
been reported previously. Our finding of a greater reduction in the PI/I ratios in subjects with 
AGT than in those with NGT may indicate that the improvement in insulin processing after 
gastric bypass is greatest in those who need it the most. By contrast, no significant reductions 
in the PI/I ratios were neither observed in the NGT group nor the AGT group after lifestyle 
intervention. However, the results correspond with those of a study reporting no reduction in 
fasting PI/I ratio in obese women with type 2 diabetes after diet induced weight loss (25). 
 Overall beta cell function was ameliorated to a greater extent after gastric bypass 
surgery than after lifestyle intervention. Since improvement in DI was independently 
associated with weight reduction, greater weight loss in the surgery groups than in the 
lifestyle groups could clearly explain some of the differences. However, it should be noted 
 

that surgical treatment also independently predicted improvements in DI and that 
improvements in stimulated PI/I ratio was associated with surgical treatment and not with 
weight reduction. The latter findings indicate that the improvements in beta cell function may 
be partly related to the surgical procedure per se and not only to weight reduction. 
 One year after surgery, post challenge glucose, insulin and c-peptide dropped sharply   
after an initial rise, with all values relatively high at 30 minutes and low at 120 minutes in 
both glucose tolerance groups. Specially worth noting is the high prevalence of post challenge 
hypoglycaemia. As demonstrated in this and previous studies, excessive insulin secretion may 
occur after gastric bypass (13, 25). Although the present study was not designed to explore the 
pathophysiological mechanisms for post bypass hyperinsulinaemia, it might be speculated that 
bypassing the gastric ventricle causes rapid absorption of glucose and consequently high 
glucose levels immediately after glucose ingestion. Indeed, we and others (13, 25) have 
reported elevated glucose levels 30 minutes after a glucose load in gastric bypass patients. 
Hyperglycaemia may in turn stimulate insulin secretion and thereby contribute to the 
observed hyperinsulinaemia. However, it is also very likely that other factors are involved, 
with a few publications recently addressing this phenomenon (13, 14). Some researchers 
argue that post-gastric bypass hyperinsulinaemia may be explained by the increase in gut 
hormones such as glucagon-like peptide 1 (GLP 1) and gastric inhibitory peptide which 
follows the rearrangement of the intestine (13, 25). Alternatively, but not mutually exclusive, 
pathologic overgrowth of pancreatic beta cells, possibly stimulated by GLP 1, after bypass 
surgery may result in hypersecretion of insulin (14). 
 Finally, improved glycaemic control caused by enhanced insulin sensitivity after 
weight loss may in turn reduce the toxic effect of glucose on the pancreatic beta cells and 
thereby increase insulin secretion. This would partly explain the improved beta cell function 
observed after lifestyle intervention in both the present study and others like it (6-8). 
 

 
Conclusions  
In summary, beta cell function improved in subjects with both normal and abnormal glucose 
tolerance after both interventions, although this was more pronounced after Roux-en-Y gastric 
bypass. Notably, supra-physiological insulin secretion and proinsulin processing may point 
towards excessive beta cell function after gastric bypass surgery. This may possibly contribute 
to improved glycaemic control in patients with abnormal glucose tolerance but also to 
postprandial hypoglycaemia observed after this procedure. Future studies addressing the same 
themes should be longitudinal, use both intravenous and oral techniques for the estimation of 
beta cell function, and include gut hormones. 
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Figure legends 
Figure 1 Mean glucose, insulin, and c-peptide during the OGTT in controls and in morbidly 
obese subjects at baseline and one year after gastric bypass surgery and intensive lifestyle 
intervention according to glucose tolerance status at baseline. Error bars represent 95 % CIs. 
Independent samples t-tests were used for the comparison of means. 
*P < 0.05, controls versus intervention groups. 
†P < 0.05, surgery versus lifestyle group. 
 
 Figure 2 Mean HOMA-S plotted against first phaseest in controls and morbidly obese subjects 
with normal glucose tolerance (A) and abnormal glucose tolerance (B) before and one year 
after gastric bypass and lifestyle intervention. The curve represents the regression line of the 
natural logarithm of estimated insulin secretion as a linear function of the natural logarithm of 
estimated insulin sensitivity for all participants with normal glucose tolerance at baseline. The 
bar graph (C) represents mean value of the corresponding disposition indices. Error bars 
represent 95 % CIs.  
 *P-value for the effect of treatment choice and glucose tolerance status at baseline on change 
in disposition index, two-way ANOVA.  
 †P < 0.05, ††P <0.001, one year versus baseline, paired samples t-test.  
 ‡P < 0.001, between groups (surgery versus lifestyle) changes in disposition index within the 
same glucose tolerance group, ANCOVA with adjusting for gender, age and BMI at baseline 
and baseline value.   
 §P < 0.001, normal glucose tolerance versus abnormal glucose tolerance within the same 
intervention group at baseline, independent samples t-test. 
 
 

 Figure 3 Mean stimulated (A) and fasting (B) proinsulin-to-insulin ratios in controls and 
morbidly obese subjects with normal and abnormal glucose tolerance before and one year 
after gastric bypass and lifestyle intervention. Error bars represent 95 % CIs.  
 *P-value for the effect of treatment choice and glucose tolerance status at baseline on change 
in disposition index, two-way ANOVA.  
 ††P < 0.001, one year versus baseline, paired samples t-test.  
 ‡P < 0.001, between groups (surgery versus lifestyle) changes in disposition index within the 
same glucose tolerance group, ANCOVA with adjusting for gender, age and BMI at baseline 
and baseline value.   
 §P < 0.001, normal glucose tolerance versus abnormal glucose tolerance within the same 
intervention group at baseline, independent samples t-test. 
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